<SEC-DOCUMENT>0001654954-17-004568.txt : 20170512
<SEC-HEADER>0001654954-17-004568.hdr.sgml : 20170512
<ACCEPTANCE-DATETIME>20170512154028
ACCESSION NUMBER:		0001654954-17-004568
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		41
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170512
DATE AS OF CHANGE:		20170512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sunshine Biopharma, Inc
		CENTRAL INDEX KEY:			0001402328
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				205566275
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52898
		FILM NUMBER:		17838314

	BUSINESS ADDRESS:	
		STREET 1:		469 JEAN-TALON WEST
		STREET 2:		3RD FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3N 1R4
		BUSINESS PHONE:		514-764-9698

	MAIL ADDRESS:	
		STREET 1:		469 JEAN-TALON WEST
		STREET 2:		3RD FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3N 1R4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mountain West Business Solutions, Inc
		DATE OF NAME CHANGE:	20071030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	mountain west business solutions,inc
		DATE OF NAME CHANGE:	20070607
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sbfm_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
U.S. SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
WASHINGTON, D.C. 20549</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; color: #000000; font-family: Times New Roman; font-size: 16px">
Form 10-Q</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Quarterly Report Under</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
the Securities Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
For Quarter Ended:&#xA0;</font><font style="font-weight: bold; text-decoration: underline; color: #000000">March
31, 2017</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Commission File Number:&#xA0;</font><font style="font-weight: bold; text-decoration: underline; color: #000000">000-52898</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 16px">
SUNSHINE BIOPHARMA INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(Exact name of small business issuer as specified in its
charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; width: 80%; font-family: Times New Roman; font-size: 13px; margin: 0px auto;">
<tr>
<td style="vertical-align: top; width: 48%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Colorado</font></div>
</td>
<td style="vertical-align: top; width: 4%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 48%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
20-5566275</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(State
of other jurisdiction of incorporation)</font></div>
</td>
<td style="vertical-align: top; width: 4%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 48%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(IRS
Employer ID No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
469 Jean-Talon West</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
3rd&#xA0;Floor</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Montreal, Quebec, Canada H3N 1R4</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(Address of principal executive offices)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
(514) 764-9698</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(Issuer&#x2019;s Telephone Number)</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days: Yes&#xA0;</font><font style="color: #000000">&#x2611;</font><font style="color: #000000">&#xA0;
No&#xA0;</font><font style="color: #000000">&#x2610;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files).
Yes&#xA0;</font><font style="color: #000000">&#x2611;</font>
<font style="color: #000000">No&#xA0;</font><font style="color: #000000">&#x2610;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of
&#x201C;large accelerated filer,&#x201D; &#x201C;accelerated
filer&#x201D;, &#x201C;smaller reporting company&#x201D;, and
&#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange
Act. (Check one)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 19%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 42%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Large
accelerated filer&#xA0; &#x2610;</font></div>
</td>
<td style="vertical-align: top; width: 38%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Accelerated
filer&#xA0; &#x2610;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 19%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 42%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Non-accelerated
filer&#xA0; &#x2610;</font></div>
</td>
<td style="vertical-align: top; width: 38%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Smaller
reporting company&#xA0; &#x2610;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 19%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 42%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company &#x2612;</font></div>
</td>
<td style="vertical-align: top; width: 38%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. &#x2610;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange
Act).&#xA0;</font><font style="color: #000000">&#x2610;</font><font style="color: #000000">&#xA0;Yes&#xA0;</font><font style="color: #000000">&#x2611;</font><font style="color: #000000">&#xA0;No</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The number of shares of the registrant&#x2019;s only class of common
stock issued and outstanding as of May 12, 2017, was 858,594,650
shares.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: rgb(255, 255, 255);">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
TABLE OF CONTENTS</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
PART I.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
FINANCIAL INFORMATION</font></div>
</div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 6%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<font style="font-size: 11px">Page No.</font></font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 6%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
1.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Financial
Statements</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Unaudited
Consolidated Balance Sheet as of March 31, 2017</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Unaudited
Consolidated Statement of Operations for the Three Month Periods
Ended March 31, 2017 and 2016</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">4</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Unaudited
Consolidated Statement of Cash Flows for the for the Three Month
Periods Ended March 31, 2017 and 2016</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Notes
to Consolidated Financial Statements</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">6</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
2.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Management&#x2019;s
Discussion and Analysis of Financial Condition and Results of
Operations</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">13</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
3.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Quantitative
and Qualitative Disclosures About Market Risk.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">18</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
4.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Controls
and Procedures.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">18</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
PART II</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
OTHER INFORMATION</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
1.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Legal
Proceedings</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">19</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item&#xA0;1A.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Risk
Factors</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">19</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
2.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Unregistered
Sales of Equity Securities and Use of Proceeds</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">19</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
3.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Defaults
Upon Senior Securities</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
4.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Mine
Safety Disclosures</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
5.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Other
Information</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Item
6.</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Exhibits</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 8%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Signatures</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 5%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">21</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td colspan="1" rowspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Sunshine
Biopharma, Inc.</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unaudited
Consolidated Balance Sheet</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 13px;">
&#xA0;</font> <font>&#xA0;</font> <font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></font><font>&#xA0;</font>
<font>&#xA0;</font> <font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></font><font>&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Unaudited</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Audited</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
March 31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
December 31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold; font-size: 11px;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2016</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">ASSETS</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
Assets:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
and cash equivalents</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,143</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">57,453</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Prepaid
expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">846</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,007</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Current Assets</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">17,989</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">58,460</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equipment
(net of $2,797 and $2,272 depreciation, resepctively)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,420</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,944</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patents
(net of $58,918 amortization and $556,120
impairment)<br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;"><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; -</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;"><br></font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
ASSETS</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">23,409</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">64,404</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">LIABILITIES
AND SHAREHOLDERS' EQUITY</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
liabilities:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
portion of notes payable</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">71,439</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">69,939</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
portion of notes payable - related party</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">183,889</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">167,032</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accounts
payable</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27,953</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,122</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
payable</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">1,171</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">9,011</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
current liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">284,452</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">274,104</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
LIABILITIES</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">284,452</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">274,104</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">COMMITMENTS
AND CONTINGENCIES</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">SHAREHOLDERS'
EQUITY (DEFICIT)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Preferred
stock, Series A $0.10 par value per share;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;Authorized
850,000 Shares; Issued</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;and
outstanding -0- shares.</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Preferred
stock, Series B $0.10 par value per share;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;Authorized
500,000 Shares; Issued</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;and
outstanding 500,000 shares.</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">50,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">50,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Common
Stock, $0.001 par value per share;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;Authorized
3,000,000,000 Shares; Issued</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;and
outstanding 817,927,983 and 769,399,858 at</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;March
31, 2017 and December 31, 2016, respectively</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">817,928</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">769,400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;Reserved for
issuance 204,918,033 at March 31, 2017<br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Capital
paid in excess of par value</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,642,783</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;"><br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,548,460</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accumulated
comprehensive income</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,903</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">394</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accumulated
(Deficit)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">(12,773,657</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">(12,577,954</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">)</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
SHAREHOLDERS' EQUITY (DEFICIT)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">(261,043</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">(209,700</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">)</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">23,409</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">64,404</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-align: left; vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">See
Accompanying Notes To These Financial
Statements.</font></div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 62%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Sunshine Biopharma, Inc.</font></div>
</td>
<td style="vertical-align: top; width: 19%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 18%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 82%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Unaudited Consolidated Statement Of Operations and Comprehensive
Loss</font></div>
</td>
<td style="vertical-align: top; width: 18%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 62%; border-bottom: 2px solid #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 19%; border-bottom: 2px solid #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 18%; border-bottom: 2px solid #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Unaudited</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Unaudited</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
3 Months</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
3 Months</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Ended</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Ended</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
March 31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
March 31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2016</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Revenue:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">General
&amp; Administrative Expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accounting</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Amortization
&amp; depreciation</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">518</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,244</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Consulting</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,937</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;"><br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,184</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Legal</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,904</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,099</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Office</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,401</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,269</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Officer
&amp; director remuneration</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">42,965</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
transfer fee</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,665</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,086</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
G &amp; A</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">108,990</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">69,682</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(Loss)
from operations</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(108,990</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(69,682</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Other
Income (expense):</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Foreign
exchange gain</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(639</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
expense</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(9,144</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(6,954</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Litigation
settlement proceeds</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
on debt conversions</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(76,929</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(253,658</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Other (Expense)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(86,712</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(235,612</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Net
(loss)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">(195,702</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">(305,294</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic
(Loss) per common share</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">0.00</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">0.00</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Weighted
Average Common Shares Outstanding</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">805,604,089</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">215,596,040</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
Income (Loss)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(195,702</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(305,294</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Other
comprehensive income:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unrealized
Gain (Loss) from foreign exchange translation</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">1,509</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">(9,991</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">)</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Comprehensive
(Loss)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">(194,193</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">(315,285</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic
(Loss) per common share</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">0.00</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">0.00</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Weighted
Average Common Shares Outstanding</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">805,604,089</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">215,596,040</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">See
Accompanying Notes To These Financial Statements.</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">4</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td colspan="2" style="vertical-align: top; width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Sunshine Biopharma, Inc.</font></div>
</td>
<td style="vertical-align: top; width: 17%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 17%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 18%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 17%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="4" style="vertical-align: top; width: 66%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Unaudited Consolidated Statement Of Cash Flows</font></div>
</td>
<td style="vertical-align: top; width: 18%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 17%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="6" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-size: 13px;">
&#xA0;</font> <font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Unaudited</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Unaudited</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
3 Months</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
3 Months</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Ended</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Ended</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
March 31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
March 31,</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="font-size: 11px; font-weight: bold;"><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2016</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
Flows From Operating Activities:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
(Loss)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(195,702</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(305,294</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Adjustments
to reconcile net loss to net cash used in</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;operating
activities:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Foreign
exchange loss</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">639</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Depreciation/Amortization</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">525</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;"><br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,244</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued for payment interest</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,022</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,120</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
on debt conversion</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">76,929</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">253,658</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued for payment of expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;"><br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(Increase)
decrease in prepaid expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">161</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(44</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Increase
(decrease) in Accounts Payable &amp; accrued expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(171</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(52,116</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Increase
(decrease) in interest payable</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(7,840</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">3,834</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
Cash Flows (used) in operations</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(108,037</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(81,598</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
Flows From Investing Activities:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Purchase
of equipment</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
Cash Flows (used) in Investing activities</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
Flows From Financing Activities:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Proceed
from note payable</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">50,256</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">82,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Note
payable used to pay expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,962</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Note
payable used to pay origionation fees &amp; interest</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">79,128</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
Cash Flows provided by financing activities</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">66,218</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">164,128</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
Increase (Decrease) In Cash and cash equivalents</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(41,819</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">82,530</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Foreign
currency translation adjustment</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,509</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(9,991</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
and cash equivalents at beginning of period</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">57,453</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">50,798</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
and cash equivalents at end of period</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">17,143</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">123,337</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Supplementary
Disclosure Of Cash Flow Information:</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued for services, licenses and other assets</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">14,400</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">100,000</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued for note conversions including interest</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">128,451</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;"><br></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">377,814</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
paid for interest</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td colspan="1" style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
paid for income taxes</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; font-size: 13px; border-bottom: 4px double rgb(0, 0, 0);">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 4px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">See
Accompanying Notes To These Financial Statements.</font></div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">5</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sunshine
Biopharma, Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Notes
To Unaudited Consolidated Financial Statements</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For The
Three Month Interim Period Ended March 31, 2017</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 1 &#x2013; Description of Business</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Mountain
West Business Solutions, Inc. (&#x201C;MWBS&#x201D;) was incorporated
on August 31, 2006 in the State of Colorado. Sunshine Etopo, Inc.
(formerly Sunshine Biopharma, Inc.) was incorporated in the State
of Colorado on August 17, 2009. Effective October 15, 2009, MWBS
was acquired by Sunshine Etopo, Inc. in a transaction classified as
a reverse acquisition. MWBS concurrently changed its name to
Sunshine Biopharma, Inc. Sunshine Etopo, Inc. has been inactive and
was recently dissolved. In July 2014, the Company formed a wholly
owned Canadian subsidiary, Sunshine Biopharma Canada Inc. The
financial statements represent the consolidated activity of
Sunshine Biopharma, Inc. and Sunshine Biopharma Canada Inc.
(hereinafter together referred to as the "Company"). The Company
was formed for the purposes of conducting research, development and
commercialization of drugs for the treatment of various forms of
cancer. The Company may also engage in any other business that is
permitted by law, as designated by the Board of Directors of the
Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s wholly owned Canadian Subsidiary, Sunshine
Biopharma Canada Inc. (&#x201C;Sunshine Canada&#x201D;) was formed
for the purposes of offering generic pharmaceutical products in
Canada and elsewhere around the world. Sunshine Canada has recently
signed licensing agreements for four (4) generic prescription drugs
for treatment of breast cancer, prostate cancer and BPH (Benign
Prostatic Hyperplasia). In addition, Sunshine Canada is currently
evaluating several other generic products for in-licensing and is
working on securing a Drug Establishment License
(&#x201C;DEL&#x201D;) and a Drug Identification Number
(&#x201C;DIN&#x201D;) per product from Health Canada. Once the DEL
and the DIN&#x2019;s are secured, Sunshine Canada will begin its
generic pharmaceuticals marketing and sales program in Canada and
overseas.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition, the Company has been and continues to work on the
development of its proprietary anticancer drug, Adva-27a. The next
series of steps in the development of Adva-27a include (i)
GMP-manufacturing of a 2-kilogram quantity of the drug, (ii)
completing requisite IND-enabling studies, and (iii) conducting
Phase I clinical trials. In the preclinical studies, Adva-27a was
shown to be effective at destroying multidrug resistant cancer
cells including Pancreatic Cancer, Breast Cancer, Lung Cancer and
Uterine Sarcoma, cells.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the last three month period the Company has continued to raise
money through stock sales and borrowings.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s activities are subject to significant risks and
uncertainties, including failing to secure additional funding to
operationalize the Company&#x2019;s generics business and
proprietary drug development program.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 2 &#x2013; Summary of Significant Accounting
Policies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px;">
See the Notes in the 2016 Form 10-K consolidated financial
statements for a complete summary of the Company&#x2019;s
significant accounting policies.</font><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
summary of significant accounting policies is presented to assist
the reader in understanding the Company's financial statements. The
consolidated financial statements and notes are representations of
the Company's management, which is responsible for their integrity
and objectivity. These accounting policies conform to generally
accepted accounting principles and have been consistently applied
in the preparation of the financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">6</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sunshine
Biopharma, Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Notes
To Unaudited Consolidated Financial Statements</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For The
Three Month Interim Period Ended March 31, 2017</font></div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
PRINCIPLES OF CONSOLIDATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
accompanying consolidated financial statements include the accounts
of the Company and its wholly owned subsidiaries. All intercompany
accounts and transactions have been eliminated in
consolidation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
USE OF ESTIMATES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
preparation of financial statements in conformity with U.S.
generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting
period. The more significant estimates and assumptions made by
management are valuation of equity instruments, depreciation of
property and equipment, and deferred tax asset valuation. Actual
results could differ from those estimates as the current economic
environment has increased the degree of uncertainty inherent in
these estimates and assumptions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
CASH AND CASH EQUIVALENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
Balance Sheets and Statement of Cash Flows, all highly liquid
investments with maturity of 90 days or less are considered to be
cash equivalents. The Company had a cash balance of $17,143 and
$57,453 as of March 31, 2017 and December 31, 2016, respectively.
At times such cash balances may be in excess of the FDIC limit of
$250,000.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
EARNINGS PER SHARE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company has adopted the FASB ASC Topic 260 regarding earnings /
loss per share, which provides for calculation of
&#x201C;basic&#x201D; and &#x201C;diluted&#x201D; earnings / loss per
share. Basic earnings / loss per share includes no dilution and is
computed by dividing net income / loss available to common
shareholders by the weighted average common shares outstanding for
the period. Diluted earnings / loss per share reflect the potential
dilution of securities that could share in the earnings of an
entity similar to fully diluted earnings / loss per
share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Other
than the Notes Payable specified under Note 4 and Note 5 below,
there were no potentially dilutive instruments outstanding during
the interim period ended March 31, 2017 or the year ended December
31, 2016.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
INCOME TAXES</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company follows the asset and liability method of accounting for
deferred income taxes. The asset and liability method requires the
recognition of deferred tax assets and liabilities for the expected
future tax consequences of temporary differences between financial
accounting and tax bases of assets and liabilities. The Company
accounts for income taxes pursuant to ASC 740. There was no
increase in liabilities for unrecognized tax benefits as a result
of this implementation. The Company recognizes accrued interest
related to unrecognized tax benefits in interest expense and
penalties in general and administrative expense.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">7</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sunshine
Biopharma, Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Notes
To Unaudited Consolidated Financial Statements</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For The
Three Month Interim Period Ended March 31, 2017</font></div>
&#xA0; <font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
FUNCTIONAL CURRENCY</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The U.S. dollar is the functional currency of the Company which is
operating in the United States. The functional currency for the
Company's Canadian subsidiary is the Canadian dollar. The Company
translates its Canadian subsidiary's financial statements into U.S.
dollars as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Assets and
liabilities are translated at the exchange rate in effect as of the
financial statement date.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Income statement
accounts are translated using the weighted average exchange rate
for the period.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company includes translation adjustments from currency exchange and
the effect of exchange rate changes on intercompany transactions of
a long-term investment nature as a separate component of
shareholders&#x2019; equity. There are currently no transactions of
a long-term investment nature, nor any gains or losses from
non-U.S. currency transactions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
REVENUE RECOGNITION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Since
inception, the Company has been focused on the research,
development and commercialization of drugs for the treatment of
various forms of cancer. Following its recent entry into the
generic pharmaceuticals business, the Company has become a fully
integrated pharmaceutical company offering generic and proprietary
drugs for the treatment of cancer and other acute and chronic
indications. The Company intends to recognize revenues from the
sales of generic pharmaceuticals, if or when they occur, at the
time the products are sold and collectability is
assured. In the
event the Company provides consulting services in the future,
revenues from such services will be recognized when the services
are rendered and invoiced.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
GOING CONCERN</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
accompanying financial statements have been prepared on a going
concern basis, which contemplates the realization of assets and the
satisfaction of liabilities in the normal course of business. Since
inception, the Company has had recurring operating losses and
negative operating cash flows. These factors raise substantial
doubt about the Company&#x2019;s ability to continue as a going
concern.</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s continuation as a going concern is dependent on its
ability to obtain additional financing to fund operations,
implement its business model, and ultimately, attain profitable
operations. The Company will need to secure additional funds
through various means, including equity and debt financing or any
similar financing. There can be no assurance that the Company will
be able to obtain additional equity or debt financing, if and when
needed, on terms acceptable to the Company, or at all. Any
additional equity or debt financing may involve substantial
dilution to the Company&#x2019;s stockholders, restrictive covenants
or high interest costs. The Company&#x2019;s long-term liquidity
also depends upon its ability to generate revenues and achieve
profitability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
accompanying financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might
be necessary should the Company be unable to continue as a going
concern.</font></div>
</div>
&#xA0;
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">8</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sunshine
Biopharma, Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Notes
To Unaudited Consolidated Financial Statements</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For The
Three Month Interim Period Ended March 31, 2017</font>&#xA0;
</div>
</div>
<br>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 3 &#x2013; Unaudited Financial Information</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
unaudited financial information included for the three month
interim period ended March 31, 2017 was taken from the books and
records of the Company without audit. However, such information
reflects all adjustments, consisting only of normal recurring
adjustments, which in the opinion of management are necessary to
reflect properly the results of the interim periods presented. The
results of operations for the three month interim period ended
March 31, 2017 are not necessarily indicative of the results
expected for the fiscal year ending December 31, 2017.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 4 &#x2013; Notes Payable</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">A Note
Payable having a face value of $21,439 and a maturity date of
December 31, 2017 was entered into on December 31, 2016. This Note
accrues interest at a rate of 12% per annum and is convertible
after December 31, 2016 into $0.001 par value Common Stock at a
price 35% below market value. The Company estimates that the fair
value of this convertible debt approximates the face value, so no
value has been assigned to the beneficial conversion
feature.</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">A Note
payable dated July 1, 2016, having a face value of $55,000 and a
principal balance of $48,500 at December 31, 2016, accrued interest
at 10%. This note was convertible into $0.001 par value Common
Stock at a price 40% below market value. During the three month
period ended March 31, 2017, a total of $48,500 in principal and
$3,022 of interest was converted into $0.001 par value Common Stock
leaving a principal balance of $-0-. In connection with this
conversion, 42,528,125 shares of $0.001 par value Common Stock
valued at $128,451 were issued generating a loss of $76,929 on
conversion.</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
February 10, 2017, the Company received net proceeds of $48,000 in
exchange for a note payable having a face value of $50,000 and
accruing interest at the rate of 8% per annum. The note, due on
November 20, 2017, is convertible after 180 days from issuance into
$0.001 par value Common Stock at a price 39% below market value.
The Company estimates that the fair value of this convertible debt
approximates the face value, so no value has been assigned to the
beneficial conversion feature. In connection with this note,
204,918,033 shares of the Company's Common Stock have been reserved
for issuance.<br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0; <font style="font-size: 13px; font-family: Times New Roman"><br>
</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">At March 31, 2017
and December 31, 2016, accrued interest on Notes Payable was
$15,124 and $9,011, respectively.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">9</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sunshine
Biopharma, Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Notes
To Unaudited Consolidated Financial Statements</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For The
Three Month Interim Period Ended March 31, 2017</font></div>
<br></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 5 &#x2013; Notes Payable Related Party</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
December 2016, the Company received monies from its CEO in exchange
for a note payable having a principal amount of $90,000 Canadian
($67,032 US) <font style="font-family: Times New Roman; font-size: 13px">&#x2019;&#x2013;</font>with
interest at 12% due March 31, 2017. The note is convertible any
time after the date of issuance into $0.001 par value Common Stock
at a price 35% below market value. The Company estimated that the
fair value of the convertible debt approximates the face value, so
no value has been assigned to the beneficial conversion feature.
Any gain or loss will be recognized at conversion. This note is
collateralized by all of the assets of the Company. In the event of
default, the interest rate will increased to 18% per annum and a
penalty of $1,000 Canadian ($752 US) per day will accrue. On March
31, 2017, the note, together with accrued interest of $3,021
Canadian ($2,271 US) and an additional principal amount of $3,000
Canadian ($2,247 US) paid to the Company on March 28,
2017, was
renewed for a 90-day period under the same terms and conditions as
the original note. The new note now having a face value of $96,021
Canadian ($72,198 US) is due on June 30, 2017.</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">A note
payable held by a private individual who became a principal
shareholder of the Company having a face value of $100,000 at
December 31, 2016 and a maturity date of March 31, 2017, accrues
interest at 12%. The Note is convertible any time from the date of
issuance into $0.001 par value Common Stock at a 35% discount from
market price. The Company estimates that the fair value of this
convertible debt approximates the face value, so no value has been
assigned to the beneficial conversion feature. On March 31, 2017,
the note&#x2019;s principal balance of $100,000 plus accrued
interest of $11,715 was renewed for a period of 90-day under the
same terms and conditions as the original note. The new note now
having a face value of $111,715 matures on June 30,
2017.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 6 &#x2013; Issuance of Common Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2017, the Company issued a total
of 48,428,125 shares of $0.001 par value Common Stock. Of these
42,428,125 shares valued at $128,451 were issued upon conversion of
outstanding notes payable, reducing the debt by $48,500 and
interest payable by $3,022 and generating a loss on conversion of
$76,929.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition, the Company issued 6,000,000 shares of $0.001 par value
Common Stock valued at $14,400 for $15,000 Canadian ($11,278 US).
The $15,000
Canadian was paid directly to a firm which was engaged to conduct a
valuation of the Company&#x2019;s patents. The difference of $3,122
was recorded as a consulting expense.<br></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10"><font style="font-family: Times New Roman; font-size: 13px;">In connection with
its convertible notes payable, the Company has 204,918,033 shares
of its Common Stock reserved for issuance at March
31,2017.</font><br></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company declared no dividends through March 31, 2017.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">10</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sunshine
Biopharma, Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Notes
To Unaudited Consolidated Financial Statements</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For The
Three Month Interim Period Ended March 31, 2017</font></div>
&#xA0; <font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 7 &#x2013; Earnings (Loss) Per Share</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Earnings
(loss) per share is computed using the weighted average number of
Common Shares outstanding during the period. The Company has
adopted ASC 260 (formerly SFAS128), &#x201C;Earnings per
Share&#x201D;.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 8 -- Generic Drugs Licenses</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In 2016, the Company entered into License Agreements for the
following four Generic Drugs:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Anastrozole
(brand name Arimidex&#xAE; by AstraZenica) for treatment of Breast
Cancer</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Letrozole
(brand name Femara&#xAE; by Novartis) for treatment of Breast
Cancer</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Bicalutamide
(brand name Casodex&#xAE; by AstraZenica) for treatment of Prostate
Cancer</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Finasteride
(brand name Propecia&#xAE; by Merck) for treatment of Benign
Prostatic Hyperplasia</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The cost of these Licenses has been fully expensed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 9 &#x2013; Financial Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For a
complete set of footnotes, reference is made to the Company&#x2019;s
Report on Form 10-K for the year ended December 31, 2016, as filed
with the Securities and Exchange Commission and the audited
financial statements and notes included therein.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 10 &#x2013; Income Taxes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Deferred
income taxes arise from the temporary differences between financial
statement and income tax recognition of net operating losses and
other items. Loss carryovers are limited under the Internal Revenue
Code should a significant change in ownership occur.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">A
deferred tax asset at each date has been offset by a 100% valuation
allowance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 11 &#x2013; Royalties Payable</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As part
of a subscription agreement entered into in 2016, the Company has
an obligation to pay a royalty of 5% of net sales on one of its
generic products (Anastrozole) for a period of three (3) years from
the date of the first sale of that product.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 12 &#x2013; Related Party Transactions</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition to the related party transactions detailed in Note 5
above, during the three month period ended March 31, 2017, the
Company paid its Officers and Directors cash compensation totaling
$42,965. $1,519 was paid to the Company&#x2019;s COO and $41,446 was
paid to the Company&#x2019;s CEO.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px;">
During the fiscal year ended December 31, 2016, Advanomics
Corporation paid on behalf of the Company $13,725 Canadian in
patenting fees. Advanomics was fully reimbursed by the Company in
January 2017.</font><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">11</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sunshine
Biopharma, Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Notes
To Unaudited Consolidated Financial Statements</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For The
Three Month Interim Period Ended March 31, 2017</font></div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Note 13 &#x2013; Subsequent Events</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
April 2017, the Company received monies in exchange for a
convertible note payable having a face value of $100,000 Canadian
(approximately $75,190 US).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
April 3, 2017, the Company sold 34,000,000 shares of its $0.001 par
value Common Stock valued at $98,600 for $85,000 Canadian
(approximately $63,912 US).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
April 24, 2017, the Company issued 6,666,667 shares of its $0.001
par value Common Stock for the purchase of laboratory equipment
valued at $22,000.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
April 26, 2017, the Company received monies in exchange for a
convertible note payable having a face value of $65,000.
<font style="font-family: Times New Roman; font-size: 13px;">In
connection with this note, 100,000,000 shares of the Company's
Common Stock have been reserved for issuance.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">12</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
PART I.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 2.&#xA0;&#xA0;&#xA0;&#xA0;MANAGEMENT&#x2019;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
The following discussion should be read in conjunction with our
consolidated financial statements and notes thereto included
herein. In connection with, and because we desire to take advantage
of, the &#x201C;safe harbor&#x201D; provisions of the Private
Securities Litigation Reform Act of 1995, we caution readers
regarding certain forward looking statements in the following
discussion and elsewhere in this report and in any other statement
made by, or on our behalf, whether or not in future filings with
the Securities and Exchange Commission. Forward looking statements
are statements not based on historical information and which relate
to future operations, strategies, financial results or other
developments. Forward looking statements are necessarily based upon
estimates and assumptions that are inherently subject to
significant business, economic and competitive uncertainties and
contingencies, many of which are beyond our control and many of
which, with respect to future business decisions, are subject to
change. These uncertainties and contingencies can affect actual
results and could cause actual results to differ materially from
those expressed in any forward looking statements made by, or on
our behalf. We disclaim any obligation to update forward looking
statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; color: #000000; font-family: Times New Roman; font-size: 13px">
Overview and History</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
were incorporated in the State of Colorado on August 31, 2006 under
the name &#x201C;Mountain West Business Solutions,
Inc.&#x201D;&#xA0;&#xA0;Until October 2009, our business was to
provide management consulting with regard to accounting, computer
and general business issues for small and home-office based
companies. Effective October 15, 2009, we executed an agreement to
acquire Sunshine Biopharma, Inc., a Colorado corporation, in
exchange for the issuance of 21,962,000 shares of our Common Stock
and 850,000 shares of Convertible Preferred Stock, each convertible
into twenty (20) shares of our Common Stock. As a result of this
transaction we changed our name to &#x201C;Sunshine Biopharma, Inc.
and our officers and directors resigned their positions with us and
were replaced by our current management. The majority of the Common
Shares and all of the Convertible Preferred Shares we issued for
this transaction were issued to Advanomics Corporation, a privately
held Canadian company (&#x201C;Advanomics&#x201D;). On December 21,
2011, Advanomics exercised its right to convert the 850,000 shares
of Series &#x201C;A&#x201D; Preferred Stock it held in our Company
into 17,000,000 shares of Common Stock.&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Following the above
detailed transactions, we began to operate as a pharmaceutical
company focusing on development of the Adva-27a anticancer
compound. We operated under a the exclusive technology license
agreement with Advanomics until December 2015, at which time we
acquired all of the worldwide right to the technology and became
direct owner of all issued and pending patents pertaining to the
Adva-27a technology. Following acquisition of the Adva-27a patents,
the exclusive license agreement with Advanomics was terminated and
Sunshine Etopo, Inc., Sunshine Biopharma Inc.&#x2019;s subsidiary
holding the exclusive license with Advanomics, was
dissolved.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In July
2014, we formed a wholly owned Canadian subsidiary, Sunshine
Biopharma Canada Inc. (&#x201C;Sunshine Canada&#x201D;), for the
purposes of offering generic pharmaceutical products in Canada and
elsewhere around the globe. Sunshine Canada has recently signed
licensing agreements for four (4) generic prescription drugs for
the treatment of cancer and BPH (Benign Prostatic
Hyperplasia).</font> <font style="font-family: Times New Roman; font-size: 13px">With our entry into
the generic pharmaceuticals business, we have become a fully
integrated pharmaceutical company offering generic and proprietary
drugs for the treatment of cancer and other acute and chronic
indications.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Our principal place of business is located at 469
Jean-Talon West, 3</font><font style="font-size: 70%; vertical-align: top; color: #000000">rd</font>
<font style="color: #000000">Floor, Montreal, Quebec, Canada H3N
1R4.&#xA0;&#xA0;Our phone number is (514) 764-9698 and our website
address is&#xA0;</font><font style="text-decoration: underline; color: #000000">www.sunshinebiopharma.com</font><font style="color: #000000">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
have not been subject to any bankruptcy, receivership or similar
proceeding.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; color: #000000; font-family: Times New Roman; font-size: 13px">
Results Of Operations</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Comparison of Results of Operations for the three months ended
March 31, 2017 and 2016</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">For
the three months ended March 31, 2017 and 2016, we did not generate
any revenues.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">General
and administrative expenses during the three month period ended
March 31, 2017 were $108,990, compared to general and
administrative expense of $69,682 incurred during the three month
period ended March 31, 2016, an increase of $39,308. This increase
is primarily attributable to an increase of approximately $43,000
in executive compensation. We also incurred increased accounting
and consulting fees, but lower legal fees during the three months
ended March 31, 2017, compared to the similar period in
2016.&#xA0;&#xA0;Most of our other expenses remained relatively
constant during the three month period ended March 31, 2017
compared to the similar period in 2016.&#xA0;&#xA0;We also incurred
$9,144 in interest expense during the three months ended March 31,
2017, compared to $6,954 in interest expense during the similar
period in 2016 as a result of decreased
borrowings.&#xA0;&#xA0;However, we incurred $76,929 in losses
arising from debt conversion during the three months ended March
31, 2017, compared to $253,658 in losses from debt conversion
during the similar period in 2016, a difference of $176,729 as a
result of a smaller amount of convertible notes outstanding. We
also received $25,000 from the settlement of litigation in 2016
that we did not receive during the three months ended March 31,
2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">

<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">As
a result, we incurred a net loss of $195,702 ($0.00 per share) for
the three month period ended March 31, 2017, compared to a net loss
of $305,294 ($0.00 per share) during the three month period ended
March 31, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Because
we did not generate any revenues since our inception, following is
our Plan of Operation.</font></div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">13</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<font style="font-weight: bold; font-variant: small-caps; color: #000000; font-family: Times New Roman; font-size: 13px">Plan
of Operation</font>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Since
inception, we have been operating as a pharmaceutical company
focused on the research, development and commercialization of
proprietary drugs for the treatment of various forms of
cancer.&#xA0;&#xA0;In July 2014, we formed Sunshine Biopharma
Canada Inc., a Canadian wholly owned subsidiary, for the purposes
of conducting generic pharmaceuticals business in Canada and
elsewhere around the world. During 2016, we intensified our
activities in the generic pharmaceuticals area as we continued to
pursue our proprietary anticancer drug development efforts.
Accordingly, we have become a fully integrated pharmaceutical
company offering generic and proprietary drugs for the treatment of
cancer and other acute and chronic indications. Below we describe
our Generic Pharmaceuticals Operations followed by our Proprietary
Drug Development Program.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 13px">
Generic Pharmaceuticals Operations</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
2016, our Canadian wholly owned subsidiary, Sunshine Biopharma
Canada Inc. (&#x201C;Sunshine Canada&#x201D;), signed Cross
Referencing Agreements with a major pharmaceutical company for four
prescription generic drugs for the treatment of Breast Cancer,
Prostate Cancer and Enlarged Prostate. We will market and sell
these new pharmaceutical products under our own Sunshine Biopharma
label. These four generic products are as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Anastrozole (brand
name Arimidex&#xAE; by AstraZeneca) for treatment of Breast
Cancer;</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Letrozole (brand
name Femara&#xAE; by Novartis) for treatment of Breast
Cancer;</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Bicalutamide (brand
name Casodex&#xAE; by AstraZenica) for treatment of Prostate
Cancer;</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Finasteride (brand
name Propecia&#xAE; by Merck) for treatment of BPH (Benign
Prostatic Hyperplasia)&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Worldwide sales of
the brand name version of these products as reported in the SEC
filing of the respective owner of the registered trademark are as
follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Arimidex&#xAE;
$232M in 2016</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Femara&#xAE; $380M
in 2014</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Casodex&#xAE; $247M
in 2016</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Propecia&#xAE;
$183M in 2015</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Sunshine Canada is
currently in the process of securing a Drug Identification Number
(&#x201C;DIN&#x201D;) for each of these products from Health Canada.
We are also working on finding an appropriate facility and
obtaining a Drug Establishment License (&#x201C;DEL&#x201D;) from
Health Canada. Upon receipt of the DEL and DIN&#x2019;s, we will be
able to accept orders for our own label SBI-Anastrozole,
SBI-Letrozole, SBI-Bicalutamide and SBI-Finasteride. We cannot
estimate the timing in our obtaining either the DIN or DEL due to
variables involved that are out of our control. The Figure below
shows our 30-Pill blister pack of Anastrozole.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="fig1.jpg" alt=""></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">We
currently have twenty three (23) additional Generic Pharmaceuticals
under review for in-licensing. While no assurances can be provided,
when completed, this will bring our Generic Products portfolio to a
total of twenty seven (27). We believe that a larger product
portfolio provides us with more opportunities and a greater reach
into the marketplace. We hope to further build our generics
portfolio of &#x201C;SBI&#x201D; label Generic Pharmaceuticals over
time.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Various
publicly available sources indicate that the worldwide sales of
generic pharmaceuticals are approximately $200 billion per year. In
the United States and Canada, the sales of generic pharmaceuticals
are approximately $50 billion and $5 billion, respectively. The
generic pharmaceuticals business is fairly competitive and there
are several multinational players in the field including Teva
(Israel), Novartis - Sandoz (Switzerland), Hospira (USA), Mylan
(Netherlands), Sanofi (France), Fresenius Kabi (Germany) and Apotex
(Canada). While no assurances can be provided, with our offering of
Canadian approved products we believe that we will be able to
access at least a small percentage of the generic pharmaceuticals
marketplace.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">As part
of a subscription agreement, we have an obligation to pay a royalty
of 5% of net sales on one of our generic products (Anastrozole) for
a period of three (3) years from the date of the first sale of that
product.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">While
no assurances can be provided and subject to the availability of
adequate financing, of which there is no assurance, we anticipate
that profits from the sales of Generic Products will be used to
finance our proprietary drug development program, including
Adva-27a, our flagship anticancer compound. In addition to
near-term revenue generation, building the generics business
infrastructure and securing the proper permits will render us
appropriately positioned for the marketing and distribution of our
proprietary Adva-27a drug candidate, provided that Adva-27a is
approved for such marketing and distribution, of which there can be
no assurance.</font></div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">14</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 13px">
Proprietary Drug Development Operations</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Our
proprietary drug development activities have been focused on the
development of a small molecule called Adva-27a for the treatment
of aggressive cancers. A Topoisomerase II inhibitor, Adva-27a has
been shown to be effective at destroying Multidrug Resistant cancer
cells including Pancreatic Cancer cells, Breast Cancer cells,
Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published
in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).
Sunshine Biopharma is direct owner of all issued and pending
worldwide patents pertaining to Adva-27a including U.S. Patent
Number 8,236,935. See &#x201C;Part I, Item 1 &#x2013; Business -
Intellectual Property.&#x201D;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="fig2.jpg" alt=""></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Summary of Adva-27a Preclinical Studies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Adva-27a is a
GEM-difluorinated C-glycoside derivative of Podophyllotoxin.
Another derivative of Podophyllotoxin called Etoposide is currently
on the market and is used to treat various types of cancer
including leukemia, lymphoma, testicular cancer, lung cancer, brain
cancer, prostate cancer, bladder cancer, colon cancer, ovarian
cancer, liver cancer and several other forms of cancer. Etoposide
is one of the most widely used anticancer drugs. Adva-27a and
Etoposide are similar in that they both attack the same target in
cancer cells, namely the DNA unwinding enzyme, Topoisomerase II.
Unlike Etoposide, and other anti-tumor drugs currently in use,
Adva-27a is able to destroy Multidrug Resistant Cancer cells.
Adva-27a is the only compound known today that is capable of
destroying Multidrug Resistant Cancer. In addition, Adva-27a has
been shown to have distinct and more desirable biological and
pharmacological properties compared to Etoposide. In side-by-side
studies using Multidrug Resistant Breast Cancer cells and Etoposide
as a reference, Adva-27a showed markedly improved cell killing
activity (see Figure below). Our preclinical studies to date have
shown that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Adva-27a is
effective at killing different types of Multidrug Resistant cancer
cells, including Pancreatic Cancer Cells (Panc-1), Breast Cancer
Cells (MCF-7/MDR), Small-Cell Lung Cancer Cells (H69AR), and
Uterine Sarcoma Cells (MES-SA/Dx5).</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Adva-27a is
unaffected by P-Glycoprotein, the enzyme responsible for making
cancer cells resistant to anti-tumor drugs.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Adva-27a has
excellent clearance time (half-life = 54 minutes) as indicated by
human microsomes stability studies and pharmacokinetics data in
rats.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Adva-27a clearance
is independent of Cytochrome P450, a mechanism that is less likely
to produce toxic intermediates.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Adva-27a is an
excellent inhibitor of Topoisomerase II with an IC50 of only 13.7
micromolar (this number has recently been reduce to 1.44 micromolar
as a result of resolving the two isomeric forms of
Adva-27a).</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Adva-27a has shown
excellent pharmacokinetics profile as indicated by studies done in
rats.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Adva-27a does not
inhibit tubulin assembly.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">These
and other preclinical data have been published in ANTICANCER
RESEARCH, a peer-reviewed International Journal of Cancer Research
and Treatment. The publication which is entitled &#x201C;Adva-27a, a
Novel Podophyllotoxin Derivative Found to Be Effective Against
Multidrug Resistant Human Cancer Cells&#x201D; [ANTICANCER RESEARCH
32: 4423-4432 (2012)] is available on our website at <font style="text-decoration: underline; color: #0563C1">www.sunshinebiopharma.com</font>.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="fig3.jpg" alt=""></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">15</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Clinical Development Path</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
early stage preclinical studies for our lead compound, Adva-27a,
were successfully completed and the results have been published in
ANTICANCER RESEARCH 32: 4423-4432 (2012). We have been delayed in
our implementation of our clinical development program due to lack
of funding. Our fund raising efforts are continuing and as soon as
adequate financing is in place we will continue our clinical
development program of Adva-27a by conducting the next sequence of
steps comprised of the following:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">GMP Manufacturing
of 2 kilogram for use in IND-Enabling Studies and Phase I Clinical
Trials</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">IND-Enabling
Studies</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Regulatory Filing
(Fast-Track Status Anticipated)</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Phase I Clinical
Trials (Pancreatic Cancer and in parallel Multidrug Resistant
Breast Cancer)</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="font-weight: bold">GMP
Manufacturing</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
November 2014, we entered into a Manufacturing Services Agreement
with Lonza Ltd. and Lonza Sales Ltd. (hereinafter jointly referred
to as &#x201C;Lonza&#x201D;), whereby we engaged Lonza to be the
manufacturer of our Adva-27a anticancer drug. In June 2015 we
received a sample of the pilot manufacturing run for evaluation.
Our laboratory analyses showed that, while the sample meets the
required biological specifications, the amount of material
generated (the &#x201C;Yield&#x201D;) by the pilot run was found to
be significantly lower than planned. During the course of our
discussions concerning the problem of the low Yield, Lonza informed
us that they required us to pay them $687,818 prior to moving
forward with any activity pertaining to the manufacturing agreement
we have with them. We have repeatedly indicated to Lonza that a
clear path defining exactly how the extremely low Yield issue would
be addressed is imperative prior to us making any payments. As of
the date of this report, neither party has changed its position.
See &#x201C;Part I, Item 3 &#x2013; Legal
Proceedings.&#x201D;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Clinical Trials</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Adva-27a&#x2019;s
initial indication will be pancreatic cancer for which there are
currently little or no treatment options available. We have
concluded an agreement with McGill University&#x2019;s Jewish
General Hospital in Montreal, Canada to conduct Phase I clinical
trials for this indication. All aspects of the planned clinical
trials in Canada will employ FDA standards at all levels. Subject
to obtaining the necessary financing, we now anticipate that Phase
I clinical trials will commence in mid-2018 and we estimate that it
will take 18 months to complete, at which time we expect to receive
limited marketing approval for &#x201C;compassionate-use&#x201D;
under the FDA and similar guidelines in Canada. See
&#x201C;Potential Near-Term Opportunities&#x201D; below.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Potential Near-Term Opportunities</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">According to the
American Cancer Society, nearly 1.5 million new cases of cancer are
diagnosed in the U.S. each year.&#xA0;&#xA0;Given the terminal and
limited treatment options available for the pancreatic cancer
indication we are planning to study, we anticipate being granted
limited marketing approval (&#x201C;compassionate-use&#x201D;) for
our Adva-27a following receipt of funding and a successful Phase I
clinical trial.&#xA0;&#xA0;There are no assurances that either will
occur.&#xA0;&#xA0;Such limited approval will allow us to make the
drug available to various hospitals and health care centers for
experimental therapy and/or &#x201C;compassionate-use&#x201D;,
thereby generating revenues in the near-term.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition, we believe that upon successful completion of Phase I
Clinical Trials we may receive one or more offers from large
pharmaceutical companies to buyout or license our drug at a
significant premium.&#xA0;&#xA0;However, there are no assurances
that our Phase I Trials will be successful, or if successful, that
any pharmaceutical companies will make an acceptable offer to
us.&#xA0;&#xA0;In the event we do not consummate such a
transaction, we will require significant capital in order to
complete the requisite additional clinical trials towards a
potential full marketing approval, of which there can be no
assurance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><img src="fig4.jpg" alt=""></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">A
Space-Filling Model of Our Anticancer Compound,
Adva-27a</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">16</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 13px">
Intellectual Property</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Effective October
8, 2015, we executed a Patent Purchase Agreement (the
&#x201C;October Purchase Agreement&#x201D;), with Advanomics, a
related party, pursuant to which we acquired all of the right,
title and interest in and to U.S. Patent Number 8,236,935 (the
&#x201C;US Patent&#x201D;) for our anticancer compound,
Adva-27a.&#xA0;&#xA0;On December 28, 2015, we executed a second
Patent Purchase Agreement (the &#x201C;December Purchase
Agreement&#x201D;), with Advanomics, pursuant to which we acquired
all of the right, title and interest in and to all of the remaining
worldwide rights covered by issued and pending patents under
PCT/FR2007/000697 and PCT/CA2014/000029 (the &#x201C;Worldwide
Patents&#x201D;) for our anticancer compound, Adva-27a.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Effective December
28, 2015, we entered into amendments (the &#x201C;Amendments&#x201D;)
of these Purchase Agreements pursuant to which the total purchase
price was reduced from $17,142,499 to $618,810, the book value of
this intellectual property on the financial statements of
Advanomics.&#xA0;&#xA0;Further, the Amendments provided for
automatic conversion of the promissory notes representing the new
purchase price into an aggregate of 321,305,415 shares of our
Common Stock once we increase our authorized capital such that
these shares can be issued.&#xA0;&#xA0;In July 2016 we increased
our authorized capital and issued the 321,305,415 Common shares to
Advanomics thereby completing all aspects of the patent purchase
arrangements and securing direct ownership of all worldwide patents
and rights pertaining to Adva-27a.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition, in 2016 we signed Cross Referencing Agreements with a
major pharmaceutical company for four (4) prescription generic
drugs for the treatment of Breast Cancer, Prostate Cancer and
Enlarged Prostate. These agreements give us the right to register
the four (4) generic products, Anastrozole, Letrozole, Bicalutamide
and Finasteride in Canada under our own label and obtain a DIN for
each in order to be able to place them on the market.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">While
no assurances can be provided, we are also planning to expand our
product line through acquisitions and/or in-licensing as well as
in-house research and development.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; color: #000000; font-family: Times New Roman; font-size: 13px">
Liquidity and Capital Resources</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">As
of March 31, 2017, we had cash or cash equivalents of
$17,143.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Net cash used in operating activities was $108,037
during the three month period ended March 31, 2017, compared to
$81,598 for the three month period ended March 31,
2016.&#xA0;&#xA0;We anticipate that overhead costs and other
expenses will increase in the future as we move forward with our
proprietary drug development activities and our efforts</font> to
become a fully integrated pharmaceutical company by offering
generic pharmaceutical products as <font style="color: #000000">discussed above.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
flows from financing activities were $66,218 for the three month
periods ended March 31, 2017, compared to $164,128 during the three
months ended March 31, 2016.&#xA0;&#xA0;Cash flows used by
investing activities were $0 for the three month periods ended
March 31, 2017 and 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2017, we issued a total of
48,428,125 shares of our Common Stock. Of these, 42,428,125 shares
valued at $128,451 were issued upon conversion of outstanding notes
payable, reducing the debt by $48,500 and interest payable by
$3,022 and generating a loss on conversion of $76,929. In addition,
we issued 6,000,000 shares of our Common Stock valued at $14,400
for $15,000 Canadian ($11,278 US). The $15,000 Canadian was paid
directly to a firm which was engaged to conduct a valuation of our
patents. We believe that having an independent valuation of our
patents will be helpful in connection with our ongoing financing
efforts.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
March 29, 2016, we issued 10,000,000 shares of our Common Stock
having a market value of $100,000 or $0.01 per share, to an
unaffiliated company that is assisting us in the development of
manufacturing, marketing, sales and distribution contracts for
various generic pharmaceuticals and biomedical products in Canada.
These services are for a two year period but the value of these
shares ($100,000) was expensed in the three month period ended
March 31, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
March 2016, our Board of Directors authorized a private offering of
our Common Stock in Canada pursuant to Regulation S promulgated
under the Securities Act of 1933, as amended, wherein we
offered&#xA0;up to 60,000,000 shares of our Common Stock at an
offering price of $0.015 Canadian per share for aggregate gross
proceeds of up to $900,000 Canadian.&#xA0;&#xA0; We accepted two
subscriptions each of 10,000,000 shares of our Common Stock for
$150,000 Canadian, aggregating $300,000 Canadian or approximately
$236,550 US.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are not generating revenue from our operations, and our ability to
implement our business plan as set forth herein will depend on the
future availability of financing. Such financing will be required
to enable us to further develop our generic pharmaceuticals
business and proprietary drug development program. We intend to
raise funds through private placements of our Common Stock and/or
debt financing. We estimate that we will require approximately $6
million ($1 million for the generic pharmaceutical operations and
$5 million for the proprietary drug development program) to fully
implement our business plan in the future and there are no
assurances that we will be able to raise this capital. While we are
engaged in discussions with various investment banking firms and
venture capitalists to provide us these funds, as of the date of
this report we have not reached any agreement with any party that
has agreed to provide us with the capital necessary to effectuate
our business plan. Our inability to obtain sufficient funds from
external sources when needed will have a material adverse effect on
our plan of operation, results of operations and financial
condition.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">17</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
cost to continue operations as they are now conducted is nominal,
but these are expected to increase as we move forward with
implementation of our business plan. We do not have sufficient
funds to cover the anticipated increase in the relevant expenses.
We need to raise additional funds in order to continue our existing
operations, to initiate R&amp;D activities, and to finance our
plans to expand our operations for the next year. If we are
successful in raising additional funds, we expect our operations
and business efforts to continue and expand. There are no
assurances this will occur.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Subsequent Events</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
April 2017 we engaged in the following transactions:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">We received monies
in exchange for a convertible note payable having a face value of
$100,000 Canadian (approximately $75,190 US).</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">We sold 34,000,000
shares of our Common Stock valued at $98,600 for $85,000 Canadian
(approximately $63,912 US).</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">We issued 6,666,667
shares of our Common Stock for the purchase of laboratory equipment
valued at $22,000.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">We received monies
in exchange for a convertible note payable having a face value of
$65,000. In connection with this note, 100,000,000 shares of our
Common Stock have been reserved for issuance.<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; color: #000000; font-family: Times New Roman; font-size: 13px">
Inflation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Although
our operations are influenced by general economic conditions, we do
not believe that inflation had a material effect on our results of
operations during the three month period ended March 31,
2017.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; color: #000000; font-family: Times New Roman; font-size: 13px">
Critical Accounting Estimates</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
discussion and analysis of our financial condition and results of
operations are based upon our consolidated financial statements,
which have been prepared in accordance with accounting principles
generally accepted in the United States. The preparation of these
consolidated financial statements requires us to make estimates and
judgments that affect the amounts of assets, liabilities, revenues
and expenses, and related disclosure of contingent assets and
liabilities. On an on-going basis, we evaluate our estimates based
on historical experience and on various other assumptions that are
believed to be reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from these estimates under
different assumptions or conditions. The following represents a
summary of our critical accounting policies, defined as those
policies that we believe are the most important to the portrayal of
our financial condition and results of operations and that require
management&#x2019;s most difficult, subjective or complex judgments,
often as a result of the need to make estimates about the effects
of matters that are inherently uncertain.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="item3"><!--anchor--></a>ITEM 3. QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are a smaller reporting company and are not required to provide the
information under this item pursuant to Regulation
S-K.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 4. CONTROLS AND PROCEDURES.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; text-decoration: underline">Disclosure
Controls and Procedures</font><font style="font-weight: bold; font-style: italic">&#xA0;</font>&#x2013;<font style="font-weight: bold; font-style: italic">&#xA0;</font>Our
management, with the participation of our Chief Executive Officer
and Chief Financial Officer, has evaluated the effectiveness of our
disclosure controls and procedures (as such term is defined in
Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of
1934, as amended (the &#x201C;Exchange Act&#x201D;) as of the end of
the period covered by this Report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">These
controls are designed to ensure that information required to be
disclosed in the reports we file or submit pursuant to the
Securities Exchange Act of 1934 is recorded, processed, summarized
and reported within the time periods specified in the rules and
forms of the Securities and Exchange Commission, and that such
information is accumulated and communicated to our management,
including our CEO/CFO to allow timely decisions regarding required
disclosure.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">18</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Based
on this evaluation, our CEO and CFO have concluded that our
disclosure controls and procedures were not effective as of March
31, 2017, at reasonable assurance level, for the following
reasons:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Ineffective control
environment and lack of qualified full-time CFO who has SEC
experience to focus on our financial affairs;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Lack of qualified
and sufficient personnel, and processes to adequately and timely
identify making any and all required public
disclosures;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Deficiencies in the
period-end reporting process and accounting policies;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Inadequate internal
controls over the application of new accounting principles or the
application of existing accounting principles to new
transactions;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Inadequate internal
controls relating to the authorization, recognition, capture, and
review of transactions, facts, circumstances, and events that could
have a material impact on the company&#x2019;s financial reporting
process;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Deficient revenue
recognition policies;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Inadequate internal
controls with respect to inventory transactions; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Improper and lack
of timely accounting for accruals such as prepaid expenses,
accounts payable and accrued liabilities.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Our
Board of Directors has assigned a priority to the short-term and
long-term improvement of our internal control over financial
reporting. We are reviewing various potential solutions to remedy
the processes that would eliminate the issues that may arise due to
the absence of separation of duties within the financial reporting
functions. Additionally, the Board of Directors will work with
management to continuously review controls and procedures to
identified deficiencies and implement remediation within our
internal controls over financial reporting and our disclosure
controls and procedures.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">We
believe that our financial statements presented in this annual
report on Form 10-K fairly present, in all material respects, our
financial position, results of operations, and cash flows for all
periods presented herein.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; text-decoration: underline">Inherent
Limitations</font> &#x2013; Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that
our disclosure controls and procedures will prevent all error and
all fraud.&#xA0;&#xA0;A control system, no matter how well
conceived and operated, can provide only reasonable, not absolute,
assurance that the objectives of the control system are
met.&#xA0;&#xA0;The design of any system of controls is based in
part upon certain assumptions about the likelihood of future
events, and there can be no assurance that any design will succeed
in achieving its stated goals under all potential future
conditions.&#xA0;&#xA0;Further, the design of a control system must
reflect the fact that there are resource constraints, and the
benefits of controls must be considered relative to their costs.
Because of the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, within our company
have been detected.&#xA0;&#xA0;These inherent limitations include
the realities that judgments in decision-making can be faulty, and
that breakdown can occur because of simple error or mistake. In
particular, many of our current processes rely upon manual reviews
and processes to ensure that neither human error nor system
weakness has resulted in erroneous reporting of financial
data.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; text-decoration: underline">Changes in
Internal Control over Financial Reporting</font> &#x2013; There were
no changes in our internal control over financial reporting during
our fiscal year ended December 31, 2016, which were identified in
conjunction with management&#x2019;s evaluation required by
paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act,
that have materially affected, or are reasonably likely to
materially affect, our internal control over financial
reporting.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
PART II. OTHER INFORMATION</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 1. LEGAL PROCEEDINGS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Other
than the matter discussed above under &#x201C;GMP
Manufacturing&#x201D; we are not party to any material legal
proceedings, nor have any such actions been threatened against
us.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 1A. RISK FACTORS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are a smaller reporting company and are not required to provide the
information under this item pursuant to Regulation
S-K.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended March 31, 2017, we issued a total of
48,428,125 shares of our Common Stock. Of these 42,428,125 shares
valued at $128,451 were issued upon conversion of outstanding notes
payable, reducing the debt by $48,500 and interest payable by
$3,022 and generating a loss on conversion of $76,929.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition, we issued 6,000,000 shares of our Common Stock valued at
$14,400 for $15,000 Canadian ($11,278 US). The $15,000 Canadian was
paid directly to a firm which was engaged to conduct a valuation of
our patents.</font></div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">19</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Subsequent Events</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
April 2017 we engaged in the following transactions:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">We received monies
in exchange for a convertible note payable having a face value of
$100,000 Canadian (approximately $75,190 US).</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">We sold 34,000,000
shares of our Common Stock valued at $98,600 for $85,000 Canadian
(approximately $63,912 US).</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">We issued 6,666,667
shares of our Common Stock for the purchase of laboratory equipment
valued at $22,000.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">We received monies
in exchange for a convertible note payable having a face value of
$65,000.In connection with this note, 100,000,000 shares of our
Common Stock have been reserved for issuance.<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
funds obtained from these transactions were used for working
capital, including the development of our new business described
above under &#x201C;Plan of Operation.&#x201D;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 3. DEFAULTS UPON SENIOR SECURITIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">None</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 4. MINE SAFETY DISCLOSURE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Not
Applicable</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 5. OTHER INFORMATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">None</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 6. EXHIBITS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td colspan="2" style="vertical-align: bottom; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman;">Exhibit
No.</font></font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman;">Description</font></font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 90%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<a href="sbfm_ex311.htm">31.1</a></font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 90%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Certification
of Chief Executive Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 90%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<a href="sbfm_ex312.htm">31.2</a></font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 90%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Certification
of Chief Financial Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 90%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: bottom; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<a href="sbfm_ex32.htm">32</a></font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 90%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Certification
of Chief Executive Officer and Chief Financial Officer Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 9%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.INS</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 90%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Instance Document*</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.SCH</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 90%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Schema Document*</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.CAL</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 90%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Calculation Linkbase Document*</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.DEF</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 90%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Definition Linkbase Document*</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.LAB</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 90%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Label Linkbase Document*</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">101.PRE</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 90%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">XBRL
Presentation Linkbase Document*</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 90%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">______________________</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">*
Pursuant to Rule 406T of Regulation S-T, these interactive data
files are not deemed filed or part of a registration statement or
prospectus for purposes of Section 11 or 12 of the Securities Act
or Section 18 of the Securities Exchange Act and otherwise not
subject to liability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of Section 12 of the Securities and Exchange
Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, thereunto duly authorized
on May 12, 2017.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 38%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SUNSHINE BIOPHARMA, INC.</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">s/ Dr.
Steve N. Slilaty</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Dr.
Steve N. Slilaty,</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Principal
Executive Officer</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">s/
Camille Sebaaly</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Camille
Sebaaly,</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Principal
Financial Officer and</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Principal
Accounting Officer</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">21</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sbfm_ex311.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 16px">
Exhibit 31.1</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
CERTIFICATION PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
18 USC, SECTION 1350,</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
AS ADOPTED PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">I,
Steve N. Slilaty, certify that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;I
have reviewed this quarterly report on Form 10-Q of Sunshine
Biopharma, Inc.;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Based
on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary in
order to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect
to the period covered by this report;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Based
on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in
this report;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;The
registrant&#x2019;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal controls over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedure to be designed under our supervision, to
ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in
which this report is being prepared;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Designed
such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">c.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Evaluated
the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based upon such
evaluation; and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">d.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Disclosed
in this report any change in the registrant&#x2019;s internal
control over financial reporting that occurred during the
registrant&#x2019;s most recent fiscal quarter (the
registrant&#x2019;s fourth quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially
affect, the registrant&#x2019;s internal control over financial
reporting; and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;The
registrant&#x2019;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the
audit committee of the registrant&#x2019;s board of directors (or
persons performing the equivalent functions):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information;
and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant&#x2019;s
internal control over financial reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 49%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Dated:
May 12, 2017</font></div>
</td>
<td style="vertical-align: top; width: 51%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">
/s/ Steve N.
Slilaty&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Steve
N. Slilaty, Chief Executive Officer</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 51%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sbfm_ex312.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 16px">
Exhibit 31.2</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
CERTIFICATION PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
18 USC, SECTION 1350,</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
AS ADOPTED PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">I,
Camille Sebaaly, certify that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;I
have reviewed this quarterly report on Form 10-Q of Sunshine
Biopharma, Inc.;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Based
on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary in
order to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect
to the period covered by this report;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Based
on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in
this report;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;The
registrant&#x2019;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal controls over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedure to be designed under our supervision, to
ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in
which this report is being prepared;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Designed
such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">c.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Evaluated
the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based upon such
evaluation; and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">d.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Disclosed
in this report any change in the registrant&#x2019;s internal
control over financial reporting that occurred during the
registrant&#x2019;s most recent fiscal quarter (the
registrant&#x2019;s fourth quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially
affect, the registrant&#x2019;s internal control over financial
reporting; and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;The
registrant&#x2019;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the
audit committee of the registrant&#x2019;s board of directors (or
persons performing the equivalent functions):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information;
and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 144px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant&#x2019;s
internal control over financial reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 49%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Dated:
May 12, 2017</font></div>
</td>
<td style="vertical-align: top; width: 51%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">
/s/ Camille
Sebaaly&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Camille
Sebaaly, Chief Financial Officer</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>sbfm_ex32.htm
<DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
<font style="font-variant: small-caps">Exhibit</font>
32</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
CERTIFICATION PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
18 USC, SECTION 1350,</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
AS ADOPTED PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with this quarterly report of Sunshine Biopharma, Inc.
(the &#x201C;Company&#x201D;) on Form 10-Q for the nine month period
ended September 30, 2016, as filed with the Securities and Exchange
Commission on May 12, 2017 (the &#x201C;Report&#x201D;), we, the
undersigned, in the capacities and on the date indicated below,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of
our knowledge:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 48px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">1.&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The Report fully
complies with the requirements of Rule 13(a) or 15(d) of the
Securities Exchange Act of 1934; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 48px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The information
contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Company.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">Dated:
May 12, 2017</font></div>
</td>
<td style="vertical-align: top; width: 51%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="text-decoration: underline">/s/ Steve N. Slilaty &#xA0; &#xA0;
&#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0;
&#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0;
&#xA0;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">Steve
N. Slilaty, Chief Executive Officer</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%;">
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 51%;">
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">Dated:
May 12, 2017</font></div>
</td>
<td style="vertical-align: top; width: 51%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="text-decoration: underline">/s/ Camille
Sebaaly&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">Camille Sebaaly,
Chief Financial Officer</font></div>
</td>
</tr></table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>fig1.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 fig1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "  .<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]$/\ @FE_
MP32_9Q^)/_!./X >(O$7P ^">O\ B#7_ (;^'=2U/4]2\#:7=7FHW4VEVTDT
M\TSP%Y)7=F9G8EF9B2237KE__P $ROV1-*N+B*Z_9\_9PMI;2#[5.DO@714:
M&'./,8&#A,_Q'BM#_@D[_P HLOV:?^R5>%__ $T6M+^TE^QC>?'GXO:9XJAU
MC2=/.B6B1P6MQI[746HLMQ!/Y5TID"F$F!00@5F#8)(4 ZT8PE*TW9&5:4XQ
MO35V9C?\$T?V0$UFWTX_L_\ [-HU"[02P6I\#:+YTR$$AE3R-Q& >0.QJ6;_
M ()A_LCV[2"3]GG]G)##<)9R!O >C#9.^W9$?W'#MO3"]3O7 Y%7-3_8>>'P
MSX9M])\06]KJWA;P5=>$K;4YM.$DY:9K0B<,&#(%6W=0H;*B;@\8/ :;_P $
MS?%$,)$WQ7U+[1(]G<S7RV\SW-S<6PLEBEDWSM&SQ"SW1OL#[I#N9@,5T1HX
M=[U+?)]_\CGE6Q"VIW^:[?YZ?([\?\$H/V6"V/\ AFK]G_(&2/\ A7ND<?\
MDO[51NO^"8_[(UC?W-K-^SU^SE#<65L+VXB?P'HRM! 2P$K@P?*A*.-QX^1O
M0U@^'_\ @G=XC\.&TO+?XC:DVN"UL+:YU&YFN[B5A:WTUSM ,X#Q.LS Q."
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M"!"H:G&A1?\ R\M\F#KUE_R[_%'86/\ P2R_9/U3SOLW[.7[/%Q]GE:"7RO
M&COY4B_>1L0<,,C(/-%O_P $L?V4+N\GMXOV<?V>9+BUVB>)/ &CEX=PRNX>
M1D9'(SU%9.H_\$^=5FO[_P"R?$;Q'9V$DSO96RWU[FUC:.X4JS_: TIW20L7
M;+'R!SS5GX:_L/\ BSP%X\LM<N/B?K6L3IXB&LW[733%-2B\IXS$T(D$8;:R
MH&P0JQ(0,C%#HT+:5/P?]?UU%[>O>SI_BC4_X=._LL_]&T_ #_PWFD?_ "/1
M_P .G?V6?^C:?@!_X;S2/_D>OH"BN,[3Y_\ ^'3O[+/_ $;3\ /_  WFD?\
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MW+C/7(]:'_X)G?LA1F4-^S]^S<# JO(#X%T7]VK8VD_N. =RX]=P]:YCP?\
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M&:=>>.M"LM#UM-2^',5K.]^U\Q.N%G17C\O;MC+[CLVY_&MG4O@IX'T?7]1
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M].>P]*N^$OA=I_B'2=*DGU*[MKK5UNC$B6ZO&GD<DL<@\CT[USQ\=ZNWA_\
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MO]I."!+14TW5HHK>*$;(M2";)(YO..P[,B.1R0R'^$(!C;6C>?M&2:QX<O+
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M#?\ =OO_  (/^%>!0?M/>-K;5] ;0O%-EX[TTP6>LZPT-A!N -K>2W>FQ&(
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MROQ@J,C(?V%?">(91+<KJ$=RUP]^L$"W4X:*&/8\@3)0"%2!Z_08K>#?V#]
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M HHHH ^ /^#H[_E!1\<_^X!_ZD&F44?\'1W_ "@H^.?_ ' /_4@TRB@#W_\
MX)._\HLOV:?^R5>%_P#TT6M?0%?/_P#P2=_Y19?LT_\ 9*O"_P#Z:+6OH"@
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MWP _\.'I'_R10!] 45\__P##V+]EG_HY;X ?^'#TC_Y(H_X>Q?LL_P#1RWP
M_P##AZ1_\D4 >]WEVMC:2S/G9$A=L#)P!G@5\A>-_P#@F#=>+?C'K/Q1\%>,
M+SX)>-?$$8COK?PS &L=80-N_P")E$659Y3T+Q>4RDG#D\GT(_\ !6#]EAA@
M_M*_L_G_ +J%I'_R11_P]B_99_Z.6^ '_AP](_\ DBNG#XNI0NZ>[^>GH]#D
MQ6"I8BRK:I?+7U6IWW[._P +IOA=X6GMK[0_#VF:I+)NNKO2KF:X&IG_ )ZN
MTX\T'_99WQV8UZ%7S_\ \/8OV6?^CEO@!_X</2/_ )(H_P"'L7[+/_1RWP _
M\.'I'_R16-6I*I)SGNS>E2C2@J<%9(^@**^?_P#A[%^RS_T<M\ /_#AZ1_\
M)%'_  ]B_99_Z.6^ '_AP](_^2*@T/H"BOG_ /X>Q?LL_P#1RWP _P##AZ1_
M\D4?\/8OV6?^CEO@!_X</2/_ )(H \ _X.CO^4%'QS_[@'_J0:917D/_  <;
M_P#!03X"_'C_ ((S?&/PIX'^-WPB\9^*=5_L3[%HVA>,=.U'4+SR]<T^63RX
2(9FD?;&CNVU3A48G@$T4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>fig2.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 fig2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "T * # 2(  A$! Q$!_\0
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M*\5URTAV@'JG_"OOVF_^BN_ G_PT6J__ #2T?\*^_:;_ .BN_ G_ ,-%JO\
M\TM>[44 >$_\*^_:;_Z*[\"?_#1:K_\ -+1_PK[]IO\ Z*[\"?\ PT6J_P#S
M2U[M6/XH^(>@>")[6+6M<T?1Y;XE;9+V\CMVN", A Y&[&Y>F?O#UH \A_X5
M]^TW_P!%=^!/_AHM5_\ FEH_X5]^TW_T5WX$_P#AHM5_^:6O=E8.H(Y!Y!'>
MB@#PG_A7W[3?_17?@3_X:+5?_FEH_P"%??M-_P#17?@3_P"&BU7_ .:6O=J*
M /"?^%??M-_]%=^!/_AHM5_^:6C_ (5]^TW_ -%=^!/_ (:+5?\ YI:]VHH
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M_*?E&[@<"J?PG_9P\)_ /4=0U739-6EN+J$6_P!IU?5Y[XV-LIR+>!IG;R8
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MU/\ ]E0LO_4+\+U[Q7@_[(7_ "<%^U/_ -E0LO\ U"_"] !\/?\ E)U\7O\
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M1UCX#Z;I_BN6RMKC6;?1KC4-+B@T'0[Q+)GCEN[)FN9;^ZF#&1W$494;&&%
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M %%%% !7@_[(7_)P7[4__94++_U"_"]>\5X/^R%_R<%^U/\ ]E0LO_4+\+T
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MH67_ *A?A>@ ^'O_ "DZ^+W_ &2_P/\ ^G;QA7O%>#_#W_E)U\7O^R7^!_\
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MJ%E_ZA?A>O>*\'_9"_Y."_:G_P"RH67_ *A?A>@ ^'O_ "DZ^+W_ &2_P/\
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M+LO7*ZAKYN;Z&2Q))&862T,L;*-Q6.7/\.0#[DKP?]D+_DX+]J?_ +*A9?\
MJ%^%ZR_V3_\ @I9X#_:G^)MYX#TRZB_X3#1K)I=0CAO+22(W$+)'=Q+"D[7<
M(BE<*&N88ED',32@$C4_9"_Y."_:G_[*A9?^H7X7H /A[_RDZ^+W_9+_  /_
M .G;QA7O%>#_  ]_Y2=?%[_LE_@?_P!.WC"O>* "BBB@ HHHH **** .)^(_
M[./@?XO:Y;ZEXF\-Z?K%]:M:O%-<!BT;6LSS0$8('R22.P_WCG(XK+T[]D+X
M<Z3X@N-2M?#<=O->:>-,N88[NX6TNH @C DM_,\F1]@5?,9"^U5&["C'I5%
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6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>fig3.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 fig3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MN18K,LMI@I:^9(GS^4\B.7R 1D@KC&>]:^OZSJ\GPWTV^:9(M0NIK99/LLH
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MU6SGF^QB(NL.YWW?.24)R"@R-WKBN[\066L>)?".ERBQDM[X7$-U-;13A'0
MY(5VQAL8Z]* .BM9]*O9W,(MWN)H@\@*?.R'H6&,X.._I5S[+;,Z.;>$NA+(
MVP9!/4@]OPKSS4?".KW6HW][96QANKO2([9+F:=3+#*K,6#E?[P(&Y:R+_PY
MJT5[:0C2'>UN9KEHM,%T D \I0,L#C.[D#/N.1B@#UM[:!Y!(\,;2+RK% 2/
MH<>]9T%KIVDZK,L<;"ZU:9I9'P6WLJ@8)[  # ^M<';>"_$L-U;+<RFYGC6
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MB 12-(T_W54<C'7<.V.]:*$D<T .HHHH **** "BBB@ HHHH **** "BBB@
MP/2BD8XZ=33<X'7]: '57C_X_I_]Q/\ V:IU.:AC_P"/Z?\ W$_]FHL!/2$
MG)'2G44K -  Z "EI:*=K; )63J?[G4=.N1QB0Q'Z,/\0*UC67KR$Z6\@^]&
MRN/;!%9U-@9IBFO%'(R,Z*S(<J2.A]J(6#Q*PZ, 14E5':X$8AC$K2*BB1@
M6QR0.G\S3\4M%4 F/:C ]*6B@!,>U&/:EHH 3%(0.].HH J_9(//DE*!I)$V
M,3S\OI[5)!;QV\0BB&$7H,]*FHH"[&XHV#T%.HH'<C,,9ZHI_"F&TMSU@B/_
M   5/11J%RJ=.LCUM(#_ -LQ4;:/IC?>T^U/UA7_  J]11J%S+;P_H[==-M/
MPB'^%1-X7T-NNEVI_P"V=;-%%V%S#_X1+0C_ ,PRW'X&HY?"&B^6?+L(P_\
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MK_GC#_W]/_Q-&^Z_YXP_]_3_ /$U/10!!ONO^>,/_?T__$T;[K_GC#_W]/\
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M=SY'B9#T6XMR/JRG_ FM@5%/:PA:***T&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%1S&01,8]N_'R[NF?>@!]%8-Y<Z[;6K2>7:MQ
MP(@Q;-1Z?=:[-:@^7;AD^4^<'#''?%8^V5[6 Z+/O32><9.:X3Q>WBB:YT]-
M,MYV:U4W4[6TOEH[!L*GS??& Q*]^*RY+SQ>VLW6J+%=[K6WE>.U:V C*B:(
MB-3_ !,T0;D\@FMD[@>H#W_G1SFO/++5O&O]NV$4MFS6\EN7F61%2)2<E1O
M)!7A3R?I3I1>W7BC4)IK+5H[>.S(>W268I=38!^1L@*%((!&,Y- 'H0I:\TT
M5_%>DZKH>FB.\EL7427DDH\U/G#LP#D%\J=@&6Z8X/;TB//.3^= #Z*** .,
M^)4;_P#"-"X@M6FG@E#HR7*0&/@_-N;@X].]3_#K49=4\'V]S-J"WTF]U,BP
M>5C!^[COCU[U#\1[47FBV<+1&:,W:>9''L\UEY_U>[C=5_P3'J,7AQ(]125'
M663R%G"^8(=QV!]O&['7'M0 >.='O->\(7NG6.#<2&-E4MM#[9%8KN[9"D9]
MZXFZ\+^*)XYYWMENA<VES9PP3W2LUJDF-K,_1@,,>,GIU[>L8!Z@&C ]!0!2
MTRU:RTRUM&D+O!"D1;/)VKC/Z4U('^V38N)!\B>GO6A5>/\ X_I_]Q/_ &:@
M!/(D_P"?F3]*/(D_Y^9/TJS10!6\B3_GYD_2CR)/^?F3]*LT4 5O(D_Y^9/T
MH^SR?\_,GZ59HH P=8A:![*[,\A\J< GCA6X-:@@DQ_Q\R?D*;JEL+O3YH/[
MRG'UI-+N3=:;#*WWRN''HPX-9;3: D\B3_GYD_2CR)/^?F3]*L"EK4"MY$G_
M #\R?I1Y$G_/S)^E6:* *WD2?\_,GZ4>1)_S\R?I5FB@"MY$G_/S)^E'D2?\
M_,GZ59HH K>1)_S\R?I1Y$G_ #\R?I5FB@"MY$G_ #\R?I1Y$G_/S)^E6:*
M*WD2?\_,GZ4>1)_S\R?I5FB@"MY$G_/S)^E'D2?\_,GZ59HH K>1)_S\R?I1
MY$G_ #\R?I5FB@"MY$G_ #\R?I1]GD_Y^9?TJS10!'$C(N&D9_\ >Q3S2U%<
MM*D#M @>4*2J$XR: ),#THKF9=4\2A5(T6$$D=+D<_I1'J?B5@W_ !)H<[L<
MW. /TI\C'8Z;%&,]:X#6M5UQ/$NDQ,\ME%+:R-)$F60RAP%&0O/';(ZU3T[Q
M?XE+:;#/ )9',8DS:2*9=SL),'&%\M1N)[_C2$>ETF!C&!@\8KRVU\?:_=VK
M2"WB6 MAKL6TC+!]\8('W_NCD<<U)-XL\27$L<<FF312J+>7R8HW!5F4%D=L
M8ZG&/2@#T[ /!&?K2BO*(?%_B2#3]0U%89+AI;NWC4- ZI;J8B6PI'.' 4GW
MS7IFE7%Q=:9;3W40BN)(E:2,9PK$<CF@"Y1110!POCN>VOV71;C39+R18?MD
M")=-;L\BL  K+SP"2:O_  ^GCN/#;^7;R0&*ZFA=7O)+H%D<J2LC_,5..*J^
M,[O2FN(;/5/#E]JH WI);QQD)[9+J16YX8GM9]#A-EID^F6Z$HEM/&J,H'LI
M(Q^- &P*6J6J:A#I6FW%_<L5A@0NY'MV'N>@^M<7_P +*D?24NTT.4W"PW%Q
M<6YN /*BA;#G=@[FSVQ^(H ]!JO%_P ?T_\ N)_[-265TE[9Q741)BFC61">
MN",]*8DL?VV;]XOW$[_6@"Y147G1_P#/1?SH\Z/_ )Z+^= $M%1>='_ST7\Z
M/.C_ .>B_G0!+147G1_\]%_.CSH_^>B_G0!(W2L>P/V+5+JQ/"2'S8L^_45J
M>;'_ ,]%_.LG7FCCM5O(Y52> Y0YZY_A_&LJONKF[ ;0YI:R=%U07^GK)(ZB
M8<.,]_7Z&M'SH_\ GHOYU<9*2O$$R6BHO.C_ .>B_G1YT?\ ST7\ZH"6BHO.
MC_YZ+^='G1_\]%_.@"6BHO.C_P">B_G1YT?_ #T7\Z ):*B\Z/\ YZ+^='G1
M_P#/1?SH EHJ+SH_^>B_G1YT?_/1?SH EHJ+SH_^>B_G1YT?_/1?SH EHJ+S
MH_\ GHOYT>='_P ]%_.@"6BHO.C_ .>B_G1YT?\ ST7\Z ):*B\Z/_GHOYT>
M='_ST7\Z ):*:CJXRK CVIU "$#THQ2T4K (% [#\J1E!X(!SUIU%,""UM;>
MSMU@MH8XH5^ZB* !DY/'UJ8J#V%+10 F/:EHHH **** .!^).G02:8M]#I-O
M>WR8!9K7SY%C&>0@Y(S@'T!K7\"%&\/%H=/2QMFGD,$2Q>63'G"L5Z@GWHUO
M2M677K;6M&%I+<1PM \%TQ4%20<JP!P?PYJUX4TBYT;2'AO)(WN9[B6ZE$0(
M1&D<L57/89H NZOI-IK>GM97RLT#.CD*Q4Y5@PY'N!7*GX:V$=L88=0O8RXG
M25RP9GCE.67GI]1SUKN:,#T'% $-K;QVMM';1)MBB01HOHH& /TJ*."$WLW[
MI/N)_"/>K=01?\?T_P#N)_[-0!)]G@_YXQ_]\BC[/!_SQC_[Y%244 1_9X/^
M>,?_ 'R*/L\'_/&/_OD5)10!']G@_P">,?\ WR*/L\'_ #QC_P"^14E% $1M
MX?\ GC'_ -\BJ]WIEG>1A)H5V@Y&WBKM%)JX&%)H*6K";30L<B]4?E7]O;ZU
M):W]I-*+>X@6VNN\4@ S]#W%;-5KRRMKV+R[B%9%]QR/H>U9\CAK$0]8(2/]
M3'_WP*=]G@_YXQ_]\BLK[!?VG_'C>%XQTBG&[\CUI?[2OK?BYTYSCJT+!A0J
MG= :GV>#_GC'_P!\BC[/!_SQC_[Y%9JZ_9YQ*TD/_72,BK,>I6DOW+J(_P#
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M>S0K(Y36AJL,\=LLUQ<HA$@80X^8=.1UK6M+G7);=91#:ONZAMR,#6I]J/\
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M!V_ 5#'_ ,?T_P#N)_[-4]01?\?T_P#N)_[-0!8HHHH **** "BBB@ HHHH
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M>E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2$ ]1FBB@ P/2C '0444 +28'I110 8'I1@9S@444 &!Z"@ #H!110
M M)@8QBBB@!<#THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>fig4.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 fig4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M\TC Y!<D?G4VM7\EA)<:=ATG5BCY.,?3ZUB03XXS7-CIJ;270][*[P7,^IN
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MH!:4X#QGIAAW^HK@Z[J=2-1<T3CG"4':044459!#:_\ 'I#_ +@_E4U0VO\
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M48 5>!78H<J*X/2KKRI-I-=E9W DC S7M'P!;J*XMX;J(Q3Q))&>JL,BIJ*
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M /.+K2=5L4+R6K.@&2T?S8KB]3B,EXTL(9B_+!1DBO>L5DZEHEM=JTL421W
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M^!%S^-A1115$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!3HY'B</&[(P.05."*;11:X[V.GLO'>L6I F:.Z3/(D7!Z>HJ^?B1>X.W3K<
M''!WMQ7$T5@\-2;NXFRQ%5*R9NZAXOUG4H_+ENO+CQ@K"-H/UK"HHK6,(P5H
MJQG*<I.\F%%%%40%%%% !6MHOB*_T-S]F97B8Y:)^5/^!K)I\7^NC_WA_.IG
M&,HVDBX2<971[)%JD_\ 9\-U/82*9(U?$1W 9[$]JHR^([B9BB$Q1GC .2?K
M74V$HC=<X((Q6O)X:T76(2);98I6Y\R+Y3FOG);L]U;'"6UYTYK3BNPP&36S
M<_#0+N:QU!AQ\J2KD?G6>W@C78I2J?9Y%'1M^,_ABD,N6E^T##G*UT-GK*[0
M-PKDUT7Q#;.8VTUI57^)77!^G-5M:NKCPYI3:CJ-G+#'O$:+N!9F/T[4XQ<G
M9";25V>DIJD1')'YUG:UXLT[1+"2[NY@B*.!GECZ#U->*WOQ-G*%;&V*DCAI
M6SCUX%<;J6KW^KS"6^N7F8= 3P/H*[:6!G)^_HCDJ8R"7NZDWB+6[GQ%KMUJ
M=R?GE;Y5[(HZ ?05ET45Z\8J*LCS)-MW84444R2:WNI[2426\SQ..C(V#74V
MOQ#U.*/;/;V]P>,,<H?TZUR%%9SI0G\2-(59P^%G:2_$?4&B*Q65O$YZ-N9L
M?A7/ZKXAU/62/MEP2@Z1H-JC\*RZ*4*%.&J14J]26C84445J8A1110 4444
M0VO_ !Z0_P"X/Y5-4-K_ ,>D/^X/Y5-4T_@1<_C844451 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI60[L****8@HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>sbfm-20170331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: Source; Value: SBFM 03312017 10Q1.xfr; Date: 2017%2D05%2D12T19:08:12Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:SBFM="http://sunshinebiopharma.com/20170331">
    <link:schemaRef xlink:href="sbfm-20170331.xsd" xlink:type="simple" />
    <xbrli:context id="From2017-01-01to2017-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-05-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2017-01-01to2017-03-31">Sunshine Biopharma, Inc</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2017-01-01to2017-03-31">0001402328</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2017-01-01to2017-03-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2017-01-01to2017-03-31">2017-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2017-01-01to2017-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2017-01-01to2017-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2017-01-01to2017-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2017-01-01to2017-03-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2017-01-01to2017-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2017-01-01to2017-03-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2017-01-01to2017-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2017-01-01to2017-03-31">2017</dei:DocumentFiscalYearFocus>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-03-31" unitRef="Shares" decimals="INF">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">850000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">850000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">5420</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">5944</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">17989</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">58460</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">846</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">1007</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">17143</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">57453</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Assets contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">23409</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">64404</us-gaap:Assets>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:Liabilities contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">284452</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">274104</us-gaap:Liabilities>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">284452</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">274104</us-gaap:LiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">1171</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">9011</us-gaap:InterestPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">27953</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">28122</us-gaap:AccountsPayableCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">183889</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">167032</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">71439</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">69939</us-gaap:NotesPayableCurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2017-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <SBFM:PreferredStockValueSeriesB contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">50000</SBFM:PreferredStockValueSeriesB>
    <SBFM:PreferredStockValueSeriesB contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">50000</SBFM:PreferredStockValueSeriesB>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">23409</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">64404</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">-261043</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">-209700</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">-12773657</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">-12577954</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">1903</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">394</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">11642783</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">11548460</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">817928</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">769400</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">2797</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2272</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">58918</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-03-31" unitRef="Shares" decimals="INF">817927983</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">769399858</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-03-31" unitRef="Shares" decimals="INF">817927983</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">769399858</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2016-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2016-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">500000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">500000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2016-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2016-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">500000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">500000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">0</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</us-gaap:SalesRevenueGoodsNet>
    <SBFM:FinancialConsulting contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">25937</SBFM:FinancialConsulting>
    <SBFM:FinancialConsulting contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">14184</SBFM:FinancialConsulting>
    <us-gaap:DepreciationAndAmortization contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">518</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">15244</us-gaap:DepreciationAndAmortization>
    <us-gaap:ProfessionalFees contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">15600</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">6800</us-gaap:ProfessionalFees>
    <us-gaap:LegalFees contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">14904</us-gaap:LegalFees>
    <us-gaap:LegalFees contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">28099</us-gaap:LegalFees>
    <SBFM:OfficerRenumerationFee contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">42965</SBFM:OfficerRenumerationFee>
    <SBFM:OfficerRenumerationFee contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</SBFM:OfficerRenumerationFee>
    <SBFM:Office contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">7401</SBFM:Office>
    <SBFM:Office contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">3269</SBFM:Office>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">1665</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">2086</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-108990</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-69682</us-gaap:OperatingIncomeLoss>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">108990</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">69682</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:InterestExpense contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">9144</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">6954</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-639</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">25000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:InducedConversionOfConvertibleDebtExpense contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">76929</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">253658</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-195702</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-305294</us-gaap:NetIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-86712</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-235612</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2017-01-01to2017-03-31" unitRef="Shares" decimals="INF">805604089</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2016-01-01to2016-03-31" unitRef="Shares" decimals="INF">215596040</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2017-01-01to2017-03-31" unitRef="USDPShares" decimals="INF">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2016-01-01to2016-03-31" unitRef="USDPShares" decimals="INF">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-194193</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-315285</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">1509</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-9991</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <SBFM:StockIssuedForPaymentInterest contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">3022</SBFM:StockIssuedForPaymentInterest>
    <SBFM:StockIssuedForPaymentInterest contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">3120</SBFM:StockIssuedForPaymentInterest>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-639</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <SBFM:StockIssuedForPaymentOfExpenses contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-14400</SBFM:StockIssuedForPaymentOfExpenses>
    <SBFM:StockIssuedForPaymentOfExpenses contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</SBFM:StockIssuedForPaymentOfExpenses>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">76929</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">253658</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-108037</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-81598</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-7840</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">3834</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-171</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-52116</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-161</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">44</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">66218</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">164128</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">79128</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <SBFM:NotePayableUsedToPayOrigionationFees contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">2000</SBFM:NotePayableUsedToPayOrigionationFees>
    <SBFM:NotePayableUsedToPayOrigionationFees contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">3000</SBFM:NotePayableUsedToPayOrigionationFees>
    <SBFM:NotePayableUsedToPayExpenses contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">13962</SBFM:NotePayableUsedToPayExpenses>
    <SBFM:NotePayableUsedToPayExpenses contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</SBFM:NotePayableUsedToPayExpenses>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">50256</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">82000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:EffectOfExchangeRateOnCash contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">1509</us-gaap:EffectOfExchangeRateOnCash>
    <us-gaap:EffectOfExchangeRateOnCash contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-9991</us-gaap:EffectOfExchangeRateOnCash>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">-41819</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">82530</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:Cash contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">17143</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">57453</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">50798</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">123337</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">128451</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">377814</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">14400</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:InterestPaid contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Mountain&#13;West Business Solutions, Inc. (&amp;#8220;MWBS&amp;#8221;) was incorporated on August 31, 2006 in the State of Colorado. Sunshine Etopo,&#13;Inc. (formerly Sunshine Biopharma, Inc.) was incorporated in the State of Colorado on August 17, 2009. Effective October 15, 2009,&#13;MWBS was acquired by Sunshine Etopo, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its&#13;name to Sunshine Biopharma, Inc. Sunshine Etopo, Inc. has been inactive and was recently dissolved. In July 2014, the Company&#13;formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. The financial statements represent the consolidated&#13;activity of Sunshine Biopharma, Inc. and Sunshine Biopharma Canada Inc. (hereinafter together referred to as the &amp;#34;Company&amp;#34;).&#13;The Company was formed for the purposes of conducting research, development and commercialization of drugs for the treatment of&#13;various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board&#13;of Directors of the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company&amp;#8217;s wholly owned Canadian Subsidiary, Sunshine Biopharma Canada Inc. (&amp;#8220;Sunshine Canada&amp;#8221;) was formed for&#13;the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has recently&#13;signed licensing agreements for four (4) generic prescription drugs for treatment of breast cancer, prostate cancer and BPH (Benign&#13;Prostatic Hyperplasia). In addition, Sunshine Canada is currently evaluating several other generic products for in-licensing and&#13;is working on securing a Drug Establishment License (&amp;#8220;DEL&amp;#8221;) and a Drug Identification Number (&amp;#8220;DIN&amp;#8221;) per&#13;product from Health Canada. Once the DEL and the DIN&amp;#8217;s are secured, Sunshine Canada will begin its generic pharmaceuticals&#13;marketing and sales program in Canada and overseas.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;addition, the Company has been and continues to work on the development of its proprietary anticancer drug, Adva-27a. The next&#13;series of steps in the development of Adva-27a include (i) GMP-manufacturing of a 2-kilogram quantity of the drug, (ii) completing&#13;requisite IND-enabling studies, and (iii) conducting Phase I clinical trials. In the preclinical studies, Adva-27a was shown to&#13;be effective at destroying multidrug resistant cancer cells including Pancreatic Cancer, Breast Cancer, Lung Cancer and Uterine&#13;Sarcoma, cells.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During&#13;the last three month period the Company has continued to raise money through stock sales and borrowings.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company&amp;#8217;s activities are subject to significant risks and uncertainties, including failing to secure additional funding&#13;to operationalize the Company&amp;#8217;s generics business and proprietary drug development program.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;See the Notes in the 2016 Form 10-K consolidated financial statements for a complete summary of the Company&amp;#8217;s significant&#13;accounting policies. This&#13;summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements.&#13;The consolidated financial statements and notes are representations of the Company's management, which is responsible for their&#13;integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently&#13;applied in the preparation of the financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;PRINCIPLES&#13;OF CONSOLIDATION&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany&#13;accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;USE&#13;OF ESTIMATES&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make&#13;estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities&#13;at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more&#13;significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment,&#13;and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased&#13;the degree of uncertainty inherent in these estimates and assumptions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;CASH&#13;AND CASH EQUIVALENTS&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;For&#13;the Balance Sheets and Statement of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered&#13;to be cash equivalents. The Company had a cash balance of $17,143 and $57,453 as of March 31, 2017 and December 31, 2016, respectively.&#13;At times such cash balances may be in excess of the FDIC limit of $250,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;EARNINGS&#13;PER SHARE&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company has adopted the FASB ASC Topic 260 regarding earnings / loss per share, which provides for calculation of &amp;#8220;basic&amp;#8221;&#13;and &amp;#8220;diluted&amp;#8221; earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing&#13;net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings&#13;/ loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted&#13;earnings / loss per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Other&#13;than the Notes Payable specified under Note 4 and Note 5 below, there were no potentially dilutive instruments outstanding during&#13;the interim period ended March 31, 2017 or the year ended December 31, 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;INCOME&#13;TAXES&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires&#13;the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between&#13;financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There&#13;was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes accrued&#13;interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expense.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;FUNCTIONAL&#13;CURRENCY&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the&#13;Company's Canadian subsidiary is the Canadian dollar. The Company translates its Canadian subsidiary's financial statements into&#13;U.S. dollars as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Assets&#13;    and liabilities are translated at the exchange rate in effect as of the financial statement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Income&#13;    statement accounts are translated using the weighted average exchange rate for the period.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions&#13;of a long-term investment nature as a separate component of shareholders&amp;#8217; equity. There are currently no transactions of&#13;a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;REVENUE&#13;RECOGNITION&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Since&#13;inception, the Company has been focused on the research, development and commercialization of drugs for the treatment of various&#13;forms of cancer. Following its recent entry into the generic pharmaceuticals business, the Company has become a fully integrated&#13;pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications.&#13;The Company intends to recognize revenues from the sales of generic pharmaceuticals, if or when they occur, at the time the products&#13;are sold and collectability is assured. In the event the Company provides consulting services in the future, revenues from&#13;such services will be recognized when the services are rendered and invoiced.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;GOING&#13;CONCERN&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and&#13;the satisfaction of liabilities in the normal course of business. Since inception, the Company has had recurring operating losses&#13;and negative operating cash flows. These factors raise substantial doubt about the Company&amp;#8217;s ability to continue as a going&#13;concern.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company&amp;#8217;s continuation as a going concern is dependent on its ability to obtain additional financing to fund operations,&#13;implement its business model, and ultimately, attain profitable operations. The Company will need to secure additional funds through&#13;various means, including equity and debt financing or any similar financing. There can be no assurance that the Company will be&#13;able to obtain additional equity or debt financing, if and when needed, on terms acceptable to the Company, or at all. Any additional&#13;equity or debt financing may involve substantial dilution to the Company&amp;#8217;s stockholders, restrictive covenants or high interest&#13;costs. The Company&amp;#8217;s long-term liquidity also depends upon its ability to generate revenues and achieve profitability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded&#13;asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue&#13;as a going concern.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;unaudited financial information included for the three month interim period ended March 31, 2017 was taken from the books and&#13;records of the Company without audit. However, such information reflects all adjustments, consisting only of normal recurring&#13;adjustments, which in the opinion of management are necessary to reflect properly the results of the interim periods presented.&#13;The results of operations for the three month interim period ended March 31, 2017 are not necessarily indicative of the results&#13;expected for the fiscal year ending December 31, 2017.&lt;/font&gt;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;A&#13;Note Payable having a face value of $21,439 and a maturity date of December 31, 2017 was entered into on December 31, 2016. This&#13;Note accrues interest at a rate of 12% per annum and is convertible after December 31, 2016 into $0.001 par value Common Stock&#13;at a price 35% below market value. The Company estimates that the fair value of this convertible debt approximates the face value,&#13;so no value has been assigned to the beneficial conversion feature.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;A&#13;Note payable dated July 1, 2016, having a face value of $55,000 and a principal balance of $48,500 at December 31, 2016, accrued&#13;interest at 10%. This note was convertible into $0.001 par value Common Stock at a price 40% below market value. During the three&#13;month period ended March 31, 2017, a total of $48,500 in principal and $3,022 of interest was converted into $0.001 par value&#13;Common Stock leaving a principal balance of $-0-. In connection with this conversion, 42,528,125 shares of $0.001 par value Common&#13;Stock valued at $128,451 were issued generating a loss of $76,929 on conversion.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;February 10, 2017, the Company received net proceeds of $48,000 in exchange for a note payable having a face value of&#13;$50,000 and accruing interest at the rate of 8% per annum. The note, due on November 20, 2017, is convertible after 180 days&#13;from issuance into $0.001 par value Common Stock at a price 39% below market value. The Company estimates that the fair value&#13;of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. In&#13;connection with this note, 204,918,033 shares of the Company&amp;#8217;s Common Stock have been reserved for issuance.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;At&#13;March 31, 2017 and December 31, 2016, accrued interest on Notes Payable was $15,124 and $9,011, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <SBFM:DebtDisclosureRelatedEntityTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian&#13;($67,032 US) &amp;#8217;&amp;#8211;with interest at 12% due March 31, 2017. The note is convertible any time after the date of issuance&#13;into $0.001 par value Common Stock at a price 35% below market value. The Company estimated that the fair value of the convertible&#13;debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be&#13;recognized at conversion. This note is collateralized by all of the assets of the Company. In the event of default, the interest&#13;rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note,&#13;together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US)&#13;paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original&#13;note. The new note now having a face value of $96,021 Canadian ($72,198 US) is due on June 30, 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;A&#13;note payable held by a private individual who became a principal shareholder of the Company having a face value of $100,000 at&#13;December 31, 2016 and a maturity date of March 31, 2017, accrues interest at 12%. The Note is convertible any time from the date&#13;of issuance into $0.001 par value Common Stock at a 35% discount from market price. The Company estimates that the fair value&#13;of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. On March&#13;31, 2017, the note&amp;#8217;s principal balance of $100,000 plus accrued interest of $11,715 was renewed for a period of 90-day under&#13;the same terms and conditions as the original note. The new note now having a face value of $111,715 matures on June 30, 2017.&lt;/font&gt;&lt;/p&gt;</SBFM:DebtDisclosureRelatedEntityTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During&#13;the three months ended March 31, 2017, the Company issued a total of 48,428,125 shares of $0.001 par value Common Stock. Of these&#13;42,428,125 shares valued at $128,451 were issued upon conversion of outstanding notes payable, reducing the debt by $48,500 and&#13;interest payable by $3,022 and generating a loss on conversion of $76,929.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;addition, the Company issued 6,000,000 shares of $0.001 par value Common Stock valued at $14,400 for $15,000&#13;Canadian ($11,278 US). The $15,000 Canadian was paid directly to a firm which was engaged to conduct a valuation of the&#13;Company&amp;#8217;s patents. The difference of $3,122 was recorded as a consulting expense.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;connection with its convertible notes payable, the Company has 204,918,033 shares of its common stock reserved for issuance&#13;at March 31, 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company declared no dividends through March 31, 2017.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Earnings&#13;(loss) per share is computed using the weighted average number of Common Shares outstanding during the period. The Company has&#13;adopted ASC 260 (formerly SFAS128), &amp;#8220;Earnings per Share&amp;#8221;.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <SBFM:GenericDrugsLicenseDisclosureTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;2016, the Company entered into License Agreements for the following four Generic Drugs:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Anastrozole&#13;    (brand name Arimidex&amp;#174; by AstraZenica) for treatment of Breast Cancer&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; padding: 0.75pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Letrozole&#13;    (brand name Femara&amp;#174; by Novartis) for treatment of Breast Cancer&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Bicalutamide&#13;    (brand name Casodex&amp;#174; by AstraZenica) for treatment of Prostate Cancer&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Finasteride&#13;    (brand name Propecia&amp;#174; by Merck) for treatment of Benign Prostatic Hyperplasia&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;cost of these Licenses has been fully expensed.&lt;/font&gt;&lt;/p&gt;</SBFM:GenericDrugsLicenseDisclosureTextBlock>
    <us-gaap:CondensedFinancialStatementsTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;For&#13;a complete set of footnotes, reference is made to the Company&amp;#8217;s Report on Form 10-K for the year ended December 31, 2016,&#13;as filed with the Securities and Exchange Commission and the audited financial statements and notes included therein.&lt;/font&gt;&lt;/p&gt;</us-gaap:CondensedFinancialStatementsTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Deferred&#13;income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses&#13;and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;A&#13;deferred tax asset at each date has been offset by a 100% valuation allowance.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <SBFM:RoyaltiesPayableDisclosureTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As&#13;part of a subscription agreement entered into in 2016, the Company has an obligation to pay a royalty of 5% of net sales on one&#13;of its generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</SBFM:RoyaltiesPayableDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;addition to the related party transactions detailed in Note 5 above, during the three month period ended March 31, 2017, the Company&#13;paid its Officers and Directors cash compensation totaling $42,965. $1,519 was paid to the Company&amp;#8217;s COO and $41,446 was&#13;paid to the Company&amp;#8217;s CEO.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During&#13;the fiscal year ended December 31, 2016, Advanomics Corporation paid on behalf of the Company $13,725 Canadian in patenting fees.&#13;Advanomics was fully reimbursed by the Company in January 2017.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;April 2017, the Company received monies in exchange for a convertible note payable having a face value of $100,000 Canadian (approximately&#13;$75,190 US).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;April 3, 2017, the Company sold 34,000,000 shares of its $0.001 par value Common Stock valued at $98,600 for $85,000&#13;Canadian (approximately $63,912 US).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;April 24, 2017, the Company issued 6,666,667 shares of its $0.001 par value Common Stock for the purchase of laboratory equipment&#13;valued at $22,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On April&#13;26, 2017, the Company received monies in exchange for a convertible note payable having a face value of $65,000. In&#13;connection with this note, 100,000,000 shares of the Company&amp;#8217;s Common Stock have been reserved for issuance.&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial&#13;statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have&#13;been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements&#13;in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect&#13;the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial&#13;statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions&#13;made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation.&#13;Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent&#13;in these estimates and assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the Balance Sheets and Statement&#13;of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company&#13;had a cash balance of $17,143 and $57,453 as of March 31, 2017 and December 31, 2016, respectively. At times such cash balances&#13;may be in excess of the FDIC limit of $250,000.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has adopted the FASB ASC&#13;Topic 260 regarding earnings / loss per share, which provides for calculation of &amp;#8220;basic&amp;#8221; and &amp;#8220;diluted&amp;#8221;&#13;earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available&#13;to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect&#13;the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per&#13;share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Other than the Notes Payable specified under Note 4 and Note&#13;5 below, there were no potentially dilutive instruments outstanding during the interim period ended March 31, 2017 or the year&#13;ended December 31, 2016.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="margin: 0; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires&#13;the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between&#13;financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There&#13;was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The U.S. dollar is the functional currency of the Company&#13;which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar.&#13;The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Income statement accounts are translated using the weighted average exchange rate for the period.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company includes translation adjustments&#13;from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as&#13;a separate component of shareholders&amp;#8217; equity. There are currently no transactions of a long-term investment nature, nor any&#13;gains or losses from non-U.S. currency transactions.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Since inception, the Company has been focused on the research,&#13;development and commercialization of drugs for the treatment of various forms of cancer. Following its recent entry into the generic&#13;pharmaceuticals business, the Company has become a fully integrated pharmaceutical company offering generic and proprietary drugs&#13;for the treatment of cancer and other acute and chronic indications. The Company intends to recognize revenues from the sales of&#13;generic pharmaceuticals, if or when they occur, at the time the products are sold and collectability is assured. In the&#13;event the Company provides consulting services in the future, revenues from such services will be recognized when the services&#13;are rendered and invoiced.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2017-01-01to2017-03-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The accompanying financial statements have been prepared on&#13;a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of&#13;business. Since inception, the Company has had recurring operating losses and negative operating cash flows. These factors raise&#13;substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The Company&amp;#8217;s continuation as a going concern is dependent&#13;on its ability to obtain additional financing to fund operations, implement its business model, and ultimately, attain profitable&#13;operations. The Company will need to secure additional funds through various means, including equity and debt financing or any&#13;similar financing. There can be no assurance that the Company will be able to obtain additional equity or debt financing, if and&#13;when needed, on terms acceptable to the Company, or at all. Any additional equity or debt financing may involve substantial dilution&#13;to the Company&amp;#8217;s stockholders, restrictive covenants or high interest costs. The Company&amp;#8217;s long-term liquidity also&#13;depends upon its ability to generate revenues and achieve profitability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The accompanying financial statements do not include any adjustments&#13;relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that&#13;might be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2017-01-01to2017-03-31" unitRef="Shares" decimals="INF">48428125</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">525</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">15244</us-gaap:DepreciationAmortizationAndAccretionNet>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2017-05-12" unitRef="Shares" decimals="INF">858594650</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2017-03-31" unitRef="Shares" decimals="INF">204918033</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>sbfm-20170331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: Source; Value: SBFM 03312017 10Q1.xfr; Date: 2017%2D05%2D12T19:08:12Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6kps7xRiXgen8uKYXQsSaaA6aPtxZp8mZlBuWp9bflqvyIiDMJTMC47y9B2cRYI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:SBFM="http://sunshinebiopharma.com/20170331" elementFormDefault="qualified" targetNamespace="http://sunshinebiopharma.com/20170331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/BalanceSheet" id="BalanceSheet">
	  <link:definition>00000002 - Statement - Balance Sheet (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/BalanceSheetParenthetical" id="BalanceSheetParenthetical">
	  <link:definition>00000003 - Statement - Balance Sheet (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/UnauditedStatementOfOperationsAndComprehensiveLoss" id="UnauditedStatementOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Unaudited Statement Of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows" id="UnauditedStatementOfCashFlows">
	  <link:definition>00000005 - Statement - Unaudited Statement Of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/DescriptionsOfBusiness" id="DescriptionsOfBusiness">
	  <link:definition>00000006 - Disclosure - 1. Descriptions of Business</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - 2. Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/UnauditedFinancialInformation" id="UnauditedFinancialInformation">
	  <link:definition>00000008 - Disclosure - 3. Unaudited Financial Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000009 - Disclosure - 4. Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NotesPayableRelatedParty" id="NotesPayableRelatedParty">
	  <link:definition>00000010 - Disclosure - 5. Notes Payable Related Party</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/IssuanceOfCommonStock" id="IssuanceOfCommonStock">
	  <link:definition>00000011 - Disclosure - 6. Issuance of Common Stock</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/EarningsLossPerShare" id="EarningsLossPerShare">
	  <link:definition>00000012 - Disclosure - 7. Earnings (Loss) per Share</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/GenericDrugsLicense" id="GenericDrugsLicense">
	  <link:definition>00000013 - Disclosure - 8. Generic Drugs License</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/FinancialStatements" id="FinancialStatements">
	  <link:definition>00000014 - Disclosure - 9. Financial Statements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000015 - Disclosure - 10. Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/RoyaltiesPayable" id="RoyaltiesPayable">
	  <link:definition>00000016 - Disclosure - 11. Royalties Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000017 - Disclosure - 12. Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000018 - Disclosure - 13. Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000021 - Disclosure - 4. Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative" id="IssuanceOfCommonStockDetailsNarrative">
	  <link:definition>00000022 - Disclosure - 6. Issuance of Common Stock (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000023 - Disclosure - 11. Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20170331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20170331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20170331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20170331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="SBFM_PreferredStockValueSeriesB" name="PreferredStockValueSeriesB" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_FinancialConsulting" name="FinancialConsulting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_OfficerRenumerationFee" name="OfficerRenumerationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_Office" name="Office" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_StockIssuedForPaymentInterest" name="StockIssuedForPaymentInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_StockIssuedForPaymentOfExpenses" name="StockIssuedForPaymentOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayableUsedToPayOrigionationFees" name="NotePayableUsedToPayOrigionationFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayableUsedToPayExpenses" name="NotePayableUsedToPayExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DebtDisclosureRelatedEntityTextBlock" name="DebtDisclosureRelatedEntityTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_GenericDrugsLicenseDisclosureTextBlock" name="GenericDrugsLicenseDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_RoyaltiesPayableDisclosureTextBlock" name="RoyaltiesPayableDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_GainFromInterestForgiveness" name="GainFromInterestForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_OtherComprehensiveIncomeAbstract" name="OtherComprehensiveIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_StockIssuedForInterest" name="StockIssuedForInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_StockIssuedForPaymentOfExpenses1" name="StockIssuedForPaymentOfExpenses1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_LoanProceedsUsedToPayExpenses" name="LoanProceedsUsedToPayExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotesPayableRelatedEntityAbstract" name="NotesPayableRelatedEntityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EarningsLossPerShareAbstract" name="EarningsLossPerShareAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_GenericDrugsLicenseAbstract" name="GenericDrugsLicenseAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_FinancialStatementsAbstract" name="FinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" name="SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_IncomeTaxesDetailsNarrativeAbstract" name="IncomeTaxesDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>sbfm-20170331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: Source; Value: SBFM 03312017 10Q1.xfr; Date: 2017%2D05%2D12T19:08:12Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/DocumentAndEntityInformation" xlink:href="sbfm-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheet" xlink:href="sbfm-20170331.xsd#BalanceSheet" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheetParenthetical" xlink:href="sbfm-20170331.xsd#BalanceSheetParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedStatementOfOperationsAndComprehensiveLoss" xlink:href="sbfm-20170331.xsd#UnauditedStatementOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows" xlink:href="sbfm-20170331.xsd#UnauditedStatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/DescriptionsOfBusiness" xlink:href="sbfm-20170331.xsd#DescriptionsOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="sbfm-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedFinancialInformation" xlink:href="sbfm-20170331.xsd#UnauditedFinancialInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayable" xlink:href="sbfm-20170331.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableRelatedParty" xlink:href="sbfm-20170331.xsd#NotesPayableRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IssuanceOfCommonStock" xlink:href="sbfm-20170331.xsd#IssuanceOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/EarningsLossPerShare" xlink:href="sbfm-20170331.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/GenericDrugsLicense" xlink:href="sbfm-20170331.xsd#GenericDrugsLicense" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/FinancialStatements" xlink:href="sbfm-20170331.xsd#FinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:href="sbfm-20170331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/RoyaltiesPayable" xlink:href="sbfm-20170331.xsd#RoyaltiesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/RelatedPartyTransactions" xlink:href="sbfm-20170331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:href="sbfm-20170331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sbfm-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="sbfm-20170331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:href="sbfm-20170331.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative" xlink:href="sbfm-20170331.xsd#IssuanceOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="sbfm-20170331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheet" xlink:title="00000002 - Statement - Balance Sheet (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_PreferredStockValueSeriesB" xlink:label="loc_SBFMPreferredStockValueSeriesB" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_SBFMPreferredStockValueSeriesB" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetParenthetical" xlink:title="00000003 - Statement - Balance Sheet (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedStatementOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Unaudited Statement Of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_FinancialConsulting" xlink:label="loc_SBFMFinancialConsulting" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_SBFMFinancialConsulting" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaapLicenseCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLicenseCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_Office" xlink:label="loc_SBFMOffice" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_SBFMOffice" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_OfficerRenumerationFee" xlink:label="loc_SBFMOfficerRenumerationFee" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_SBFMOfficerRenumerationFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaapSalesRevenueGoodsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSalesRevenueGoodsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_GainFromInterestForgiveness" xlink:label="loc_SBFMGainFromInterestForgiveness" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SBFMGainFromInterestForgiveness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows" xlink:title="00000005 - Statement - Unaudited Statement Of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForPaymentInterest" xlink:label="loc_SBFMStockIssuedForPaymentInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SBFMStockIssuedForPaymentInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForPaymentOfExpenses" xlink:label="loc_SBFMStockIssuedForPaymentOfExpenses" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SBFMStockIssuedForPaymentOfExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaapDepreciationAmortizationAndAccretionNet" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAmortizationAndAccretionNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotePayableUsedToPayExpenses" xlink:label="loc_SBFMNotePayableUsedToPayExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SBFMNotePayableUsedToPayExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotePayableUsedToPayOrigionationFees" xlink:label="loc_SBFMNotePayableUsedToPayOrigionationFees" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SBFMNotePayableUsedToPayOrigionationFees" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionsOfBusiness" xlink:title="00000006 - Disclosure - 1. Descriptions of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 2. Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedFinancialInformation" xlink:title="00000008 - Disclosure - 3. Unaudited Financial Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayable" xlink:title="00000009 - Disclosure - 4. Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableRelatedParty" xlink:title="00000010 - Disclosure - 5. Notes Payable Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IssuanceOfCommonStock" xlink:title="00000011 - Disclosure - 6. Issuance of Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsLossPerShare" xlink:title="00000012 - Disclosure - 7. Earnings (Loss) per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/GenericDrugsLicense" xlink:title="00000013 - Disclosure - 8. Generic Drugs License" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/FinancialStatements" xlink:title="00000014 - Disclosure - 9. Financial Statements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - 10. Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/RoyaltiesPayable" xlink:title="00000016 - Disclosure - 11. Royalties Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - 12. Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - 13. Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000021 - Disclosure - 4. Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative" xlink:title="00000022 - Disclosure - 6. Issuance of Common Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000023 - Disclosure - 11. Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>sbfm-20170331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: Source; Value: SBFM 03312017 10Q1.xfr; Date: 2017%2D05%2D12T19:08:12Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/DocumentAndEntityInformation" xlink:href="sbfm-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheet" xlink:href="sbfm-20170331.xsd#BalanceSheet" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheetParenthetical" xlink:href="sbfm-20170331.xsd#BalanceSheetParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedStatementOfOperationsAndComprehensiveLoss" xlink:href="sbfm-20170331.xsd#UnauditedStatementOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows" xlink:href="sbfm-20170331.xsd#UnauditedStatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/DescriptionsOfBusiness" xlink:href="sbfm-20170331.xsd#DescriptionsOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="sbfm-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedFinancialInformation" xlink:href="sbfm-20170331.xsd#UnauditedFinancialInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayable" xlink:href="sbfm-20170331.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableRelatedParty" xlink:href="sbfm-20170331.xsd#NotesPayableRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IssuanceOfCommonStock" xlink:href="sbfm-20170331.xsd#IssuanceOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/EarningsLossPerShare" xlink:href="sbfm-20170331.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/GenericDrugsLicense" xlink:href="sbfm-20170331.xsd#GenericDrugsLicense" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/FinancialStatements" xlink:href="sbfm-20170331.xsd#FinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:href="sbfm-20170331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/RoyaltiesPayable" xlink:href="sbfm-20170331.xsd#RoyaltiesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/RelatedPartyTransactions" xlink:href="sbfm-20170331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:href="sbfm-20170331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sbfm-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="sbfm-20170331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:href="sbfm-20170331.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative" xlink:href="sbfm-20170331.xsd#IssuanceOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="sbfm-20170331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheet" xlink:title="00000002 - Statement - Balance Sheet (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetParenthetical" xlink:title="00000003 - Statement - Balance Sheet (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_70" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedStatementOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Unaudited Statement Of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows" xlink:title="00000005 - Statement - Unaudited Statement Of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionsOfBusiness" xlink:title="00000006 - Disclosure - 1. Descriptions of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 2. Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedFinancialInformation" xlink:title="00000008 - Disclosure - 3. Unaudited Financial Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayable" xlink:title="00000009 - Disclosure - 4. Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableRelatedParty" xlink:title="00000010 - Disclosure - 5. Notes Payable Related Party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IssuanceOfCommonStock" xlink:title="00000011 - Disclosure - 6. Issuance of Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsLossPerShare" xlink:title="00000012 - Disclosure - 7. Earnings (Loss) per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/GenericDrugsLicense" xlink:title="00000013 - Disclosure - 8. Generic Drugs License" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/FinancialStatements" xlink:title="00000014 - Disclosure - 9. Financial Statements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - 10. Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/RoyaltiesPayable" xlink:title="00000016 - Disclosure - 11. Royalties Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - 12. Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - 13. Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000021 - Disclosure - 4. Notes Payable (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative" xlink:title="00000022 - Disclosure - 6. Issuance of Common Stock (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000023 - Disclosure - 11. Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>sbfm-20170331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: Source; Value: SBFM 03312017 10Q1.xfr; Date: 2017%2D05%2D12T19:08:12Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_DocumentAndEntityInformationAbstract" xlink:label="SBFM_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DocumentAndEntityInformationAbstract" xlink:to="SBFM_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment (net of $2,797 and $2,272 depreciation, resepctively)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Patents (net of $58,918 amortization and $556,120 impairment)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Current portion of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Current portion of notes payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS' (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, Series A $0.10 par value per share; Authorized 850,000 Shares; Issued and outstanding -0- shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_PreferredStockValueSeriesB" xlink:label="SBFM_PreferredStockValueSeriesB" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreferredStockValueSeriesB" xlink:to="SBFM_PreferredStockValueSeriesB_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreferredStockValueSeriesB_lbl" xml:lang="en-US">Preferred stock, Series B $0.10 par value per share; Authorized 500,000 Shares; Issued and outstanding 500,000 shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 817,927,983 and 769,399,858 at March 31, 2017 and December 31, 2016, respectively. Reserved for issuance 204,918,033 at March 31, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Capital paid in excess of par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation, equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Amortization, patent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock shares reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Revenue:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General &amp; Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Amortization &amp; depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_FinancialConsulting" xlink:label="SBFM_FinancialConsulting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_FinancialConsulting" xlink:to="SBFM_FinancialConsulting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_FinancialConsulting_lbl" xml:lang="en-US">Consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseCosts" xlink:to="us-gaap_LicenseCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US">Licenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_Office" xlink:label="SBFM_Office" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_Office" xlink:to="SBFM_Office_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_Office_lbl" xml:lang="en-US">Office</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_OfficerRenumerationFee" xlink:label="SBFM_OfficerRenumerationFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_OfficerRenumerationFee" xlink:to="SBFM_OfficerRenumerationFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_OfficerRenumerationFee_lbl" xml:lang="en-US">Officer &amp; director renumeration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Stock Transfer Fee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="us-gaap_TravelAndEntertainmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Travel</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total G &amp; A</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">(Loss) from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_GainFromInterestForgiveness" xlink:label="SBFM_GainFromInterestForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_GainFromInterestForgiveness" xlink:to="SBFM_GainFromInterestForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_GainFromInterestForgiveness_lbl" xml:lang="en-US">Gain from interest forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xml:lang="en-US">Litigation settlement proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Debt release</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="us-gaap_InducedConversionOfConvertibleDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense_lbl" xml:lang="en-US">Loss on debt conversions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (Loss) per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Oustanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_OtherComprehensiveIncomeAbstract" xlink:label="SBFM_OtherComprehensiveIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_OtherComprehensiveIncomeAbstract" xlink:to="SBFM_OtherComprehensiveIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other comprehensive income:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_lbl" xml:lang="en-US">Unrealized Gain (Loss) from Foreign Exchange Translations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Common Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Gain (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForPaymentInterest" xlink:label="SBFM_StockIssuedForPaymentInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_StockIssuedForPaymentInterest" xlink:to="SBFM_StockIssuedForPaymentInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_StockIssuedForPaymentInterest_lbl" xml:lang="en-US">Stock issued for payment interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Debt forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Loss on debt conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForPaymentOfExpenses" xlink:label="SBFM_StockIssuedForPaymentOfExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_StockIssuedForPaymentOfExpenses" xlink:to="SBFM_StockIssuedForPaymentOfExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SBFM_StockIssuedForPaymentOfExpenses_lbl" xml:lang="en-US">Stock issued for payment of expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">(Increase) decrease in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (decrease) in Accounts Payable &amp; accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Increase (decrease) in interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Flows (used) in operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Purchase of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Flows (used) in Investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceed from note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotePayableUsedToPayExpenses" xlink:label="SBFM_NotePayableUsedToPayExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayableUsedToPayExpenses" xlink:to="SBFM_NotePayableUsedToPayExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayableUsedToPayExpenses_lbl" xml:lang="en-US">Note payable used to pay expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotePayableUsedToPayOrigionationFees" xlink:label="SBFM_NotePayableUsedToPayOrigionationFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayableUsedToPayOrigionationFees" xlink:to="SBFM_NotePayableUsedToPayOrigionationFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayableUsedToPayOrigionationFees_lbl" xml:lang="en-US">Note payable used to pay origionation fees &amp; interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net Increase (Decrease) In Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCash" xlink:label="us-gaap_EffectOfExchangeRateOnCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCash" xlink:to="us-gaap_EffectOfExchangeRateOnCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCash_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplementary Disclosure Of Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock issued for services, licenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock issued for note conversions including interest</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForInterest" xlink:label="SBFM_StockIssuedForInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_StockIssuedForInterest" xlink:to="SBFM_StockIssuedForInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_StockIssuedForInterest_lbl" xml:lang="en-US">Stock issued for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForPaymentOfExpenses1" xlink:label="SBFM_StockIssuedForPaymentOfExpenses1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_StockIssuedForPaymentOfExpenses1" xlink:to="SBFM_StockIssuedForPaymentOfExpenses1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_StockIssuedForPaymentOfExpenses1_lbl" xml:lang="en-US">Stock issued for payment of expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_LoanProceedsUsedToPayExpenses" xlink:label="SBFM_LoanProceedsUsedToPayExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_LoanProceedsUsedToPayExpenses" xlink:to="SBFM_LoanProceedsUsedToPayExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_LoanProceedsUsedToPayExpenses_lbl" xml:lang="en-US">Loan proceeds used to pay expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">1. Descriptions of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">2. Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">3. Unaudited Financial Information</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotesToFinancialStatementsAbstract" xlink:label="SBFM_NotesToFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotesToFinancialStatementsAbstract" xlink:to="SBFM_NotesToFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">4. Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotesPayableRelatedEntityAbstract" xlink:label="SBFM_NotesPayableRelatedEntityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotesPayableRelatedEntityAbstract" xlink:to="SBFM_NotesPayableRelatedEntityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotesPayableRelatedEntityAbstract_lbl" xml:lang="en-US">Notes Payable Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_DebtDisclosureRelatedEntityTextBlock" xlink:label="SBFM_DebtDisclosureRelatedEntityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DebtDisclosureRelatedEntityTextBlock" xlink:to="SBFM_DebtDisclosureRelatedEntityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DebtDisclosureRelatedEntityTextBlock_lbl" xml:lang="en-US">5. Notes Payable Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US">Text Block [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">6. Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_EarningsLossPerShareAbstract" xlink:label="SBFM_EarningsLossPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EarningsLossPerShareAbstract" xlink:to="SBFM_EarningsLossPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EarningsLossPerShareAbstract_lbl" xml:lang="en-US">Earnings Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">7. Earnings (Loss) per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_GenericDrugsLicenseAbstract" xlink:label="SBFM_GenericDrugsLicenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_GenericDrugsLicenseAbstract" xlink:to="SBFM_GenericDrugsLicenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_GenericDrugsLicenseAbstract_lbl" xml:lang="en-US">Generic Drugs License</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_GenericDrugsLicenseDisclosureTextBlock" xlink:label="SBFM_GenericDrugsLicenseDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_GenericDrugsLicenseDisclosureTextBlock" xlink:to="SBFM_GenericDrugsLicenseDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_GenericDrugsLicenseDisclosureTextBlock_lbl" xml:lang="en-US">8. Generic Drugs License</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_FinancialStatementsAbstract" xlink:label="SBFM_FinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_FinancialStatementsAbstract" xlink:to="SBFM_FinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_FinancialStatementsAbstract_lbl" xml:lang="en-US">Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CondensedFinancialStatementsTextBlock" xlink:label="us-gaap_CondensedFinancialStatementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialStatementsTextBlock" xlink:to="us-gaap_CondensedFinancialStatementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CondensedFinancialStatementsTextBlock_lbl" xml:lang="en-US">9. Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">10. Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_RoyaltiesPayableDisclosureTextBlock" xlink:label="SBFM_RoyaltiesPayableDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_RoyaltiesPayableDisclosureTextBlock" xlink:to="SBFM_RoyaltiesPayableDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_RoyaltiesPayableDisclosureTextBlock_lbl" xml:lang="en-US">11. Royalties Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">12. Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">13. Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">PRINCIPLES OF CONSOLIDATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">USE OF ESTIMATES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">EARNINGS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">FOREIGN CURRENCY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:to="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_lbl" xml:lang="en-US">AMORTIZATION AND DEPRECIATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:label="SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:to="SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies Details Narrative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_2_lbl" xml:lang="en-US">Interest accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Par value of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_IncomeTaxesDetailsNarrativeAbstract" xlink:label="SBFM_IncomeTaxesDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_IncomeTaxesDetailsNarrativeAbstract" xlink:to="SBFM_IncomeTaxesDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_IncomeTaxesDetailsNarrativeAbstract_lbl" xml:lang="en-US">Income Taxes Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred tax asset, operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in the valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_FinancialConsulting" xlink:to="SBFM_FinancialConsulting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SBFM_FinancialConsulting_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_Office" xlink:to="SBFM_Office_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SBFM_Office_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="us-gaap_InducedConversionOfConvertibleDebtExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense_2_lbl" xml:lang="en-US">Induced Conversion of Convertible Debt Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_StockIssuedForPaymentOfExpenses" xlink:to="SBFM_StockIssuedForPaymentOfExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_StockIssuedForPaymentOfExpenses_2_lbl" xml:lang="en-US">StockIssuedForPaymentOfExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>sbfm-20170331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: Source; Value: SBFM 03312017 10Q1.xfr; Date: 2017%2D05%2D12T19:08:12Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/DocumentAndEntityInformation" xlink:href="sbfm-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheet" xlink:href="sbfm-20170331.xsd#BalanceSheet" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/BalanceSheetParenthetical" xlink:href="sbfm-20170331.xsd#BalanceSheetParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedStatementOfOperationsAndComprehensiveLoss" xlink:href="sbfm-20170331.xsd#UnauditedStatementOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows" xlink:href="sbfm-20170331.xsd#UnauditedStatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/DescriptionsOfBusiness" xlink:href="sbfm-20170331.xsd#DescriptionsOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="sbfm-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedFinancialInformation" xlink:href="sbfm-20170331.xsd#UnauditedFinancialInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayable" xlink:href="sbfm-20170331.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableRelatedParty" xlink:href="sbfm-20170331.xsd#NotesPayableRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IssuanceOfCommonStock" xlink:href="sbfm-20170331.xsd#IssuanceOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/EarningsLossPerShare" xlink:href="sbfm-20170331.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/GenericDrugsLicense" xlink:href="sbfm-20170331.xsd#GenericDrugsLicense" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/FinancialStatements" xlink:href="sbfm-20170331.xsd#FinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:href="sbfm-20170331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/RoyaltiesPayable" xlink:href="sbfm-20170331.xsd#RoyaltiesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/RelatedPartyTransactions" xlink:href="sbfm-20170331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:href="sbfm-20170331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sbfm-20170331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="sbfm-20170331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:href="sbfm-20170331.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative" xlink:href="sbfm-20170331.xsd#IssuanceOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="sbfm-20170331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_DocumentAndEntityInformationAbstract" xlink:label="loc_SBFMDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheet" xlink:title="00000002 - Statement - Balance Sheet (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_PreferredStockValueSeriesB" xlink:label="loc_SBFMPreferredStockValueSeriesB" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_SBFMPreferredStockValueSeriesB" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetParenthetical" xlink:title="00000003 - Statement - Balance Sheet (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedStatementOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Unaudited Statement Of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaapSalesRevenueGoodsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSalesRevenueGoodsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_FinancialConsulting" xlink:label="loc_SBFMFinancialConsulting" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMFinancialConsulting" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaapLicenseCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLicenseCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_Office" xlink:label="loc_SBFMOffice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMOffice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_OfficerRenumerationFee" xlink:label="loc_SBFMOfficerRenumerationFee" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMOfficerRenumerationFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_GainFromInterestForgiveness" xlink:label="loc_SBFMGainFromInterestForgiveness" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SBFMGainFromInterestForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_OtherComprehensiveIncomeAbstract" xlink:label="loc_SBFMOtherComprehensiveIncomeAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMOtherComprehensiveIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMOtherComprehensiveIncomeAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMOtherComprehensiveIncomeAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_2" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMOtherComprehensiveIncomeAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMOtherComprehensiveIncomeAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows" xlink:title="00000005 - Statement - Unaudited Statement Of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaapDepreciationAmortizationAndAccretionNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAmortizationAndAccretionNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForPaymentInterest" xlink:label="loc_SBFMStockIssuedForPaymentInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SBFMStockIssuedForPaymentInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForPaymentOfExpenses" xlink:label="loc_SBFMStockIssuedForPaymentOfExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SBFMStockIssuedForPaymentOfExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotePayableUsedToPayExpenses" xlink:label="loc_SBFMNotePayableUsedToPayExpenses" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SBFMNotePayableUsedToPayExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotePayableUsedToPayOrigionationFees" xlink:label="loc_SBFMNotePayableUsedToPayOrigionationFees" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SBFMNotePayableUsedToPayOrigionationFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCash" xlink:label="loc_us-gaapEffectOfExchangeRateOnCash" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForInterest" xlink:label="loc_SBFMStockIssuedForInterest" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SBFMStockIssuedForInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_StockIssuedForPaymentOfExpenses1" xlink:label="loc_SBFMStockIssuedForPaymentOfExpenses1" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SBFMStockIssuedForPaymentOfExpenses1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_LoanProceedsUsedToPayExpenses" xlink:label="loc_SBFMLoanProceedsUsedToPayExpenses" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SBFMLoanProceedsUsedToPayExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionsOfBusiness" xlink:title="00000006 - Disclosure - 1. Descriptions of Business">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 2. Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedFinancialInformation" xlink:title="00000008 - Disclosure - 3. Unaudited Financial Information">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaapQuarterlyFinancialInformationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapQuarterlyFinancialInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayable" xlink:title="00000009 - Disclosure - 4. Notes Payable">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotesToFinancialStatementsAbstract" xlink:label="loc_SBFMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableRelatedParty" xlink:title="00000010 - Disclosure - 5. Notes Payable Related Party">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotesPayableRelatedEntityAbstract" xlink:label="loc_SBFMNotesPayableRelatedEntityAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_DebtDisclosureRelatedEntityTextBlock" xlink:label="loc_SBFMDebtDisclosureRelatedEntityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMNotesPayableRelatedEntityAbstract" xlink:to="loc_SBFMDebtDisclosureRelatedEntityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IssuanceOfCommonStock" xlink:title="00000011 - Disclosure - 6. Issuance of Common Stock">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaapTextBlockAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTextBlockAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsLossPerShare" xlink:title="00000012 - Disclosure - 7. Earnings (Loss) per Share">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_EarningsLossPerShareAbstract" xlink:label="loc_SBFMEarningsLossPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMEarningsLossPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/GenericDrugsLicense" xlink:title="00000013 - Disclosure - 8. Generic Drugs License">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_GenericDrugsLicenseAbstract" xlink:label="loc_SBFMGenericDrugsLicenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_GenericDrugsLicenseDisclosureTextBlock" xlink:label="loc_SBFMGenericDrugsLicenseDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMGenericDrugsLicenseAbstract" xlink:to="loc_SBFMGenericDrugsLicenseDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/FinancialStatements" xlink:title="00000014 - Disclosure - 9. Financial Statements">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_FinancialStatementsAbstract" xlink:label="loc_SBFMFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CondensedFinancialStatementsTextBlock" xlink:label="loc_us-gaapCondensedFinancialStatementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMFinancialStatementsAbstract" xlink:to="loc_us-gaapCondensedFinancialStatementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - 10. Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/RoyaltiesPayable" xlink:title="00000016 - Disclosure - 11. Royalties Payable">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotesToFinancialStatementsAbstract" xlink:label="loc_SBFMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_RoyaltiesPayableDisclosureTextBlock" xlink:label="loc_SBFMRoyaltiesPayableDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMNotesToFinancialStatementsAbstract" xlink:to="loc_SBFMRoyaltiesPayableDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - 12. Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - 13. Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotesToFinancialStatementsAbstract" xlink:label="loc_SBFMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:label="loc_us-gaapDepreciationDepletionAndAmortizationPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortizationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:label="loc_SBFMSummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMSummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000021 - Disclosure - 4. Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_NotesToFinancialStatementsAbstract" xlink:label="loc_SBFMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative" xlink:title="00000022 - Disclosure - 6. Issuance of Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaapTextBlockAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaapCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTextBlockAbstract" xlink:to="loc_us-gaapCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000023 - Disclosure - 11. Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20170331.xsd#SBFM_IncomeTaxesDetailsNarrativeAbstract" xlink:label="loc_SBFMIncomeTaxesDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMIncomeTaxesDetailsNarrativeAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMIncomeTaxesDetailsNarrativeAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMIncomeTaxesDetailsNarrativeAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMIncomeTaxesDetailsNarrativeAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720055520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>May 12, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sunshine Biopharma, Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001402328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,594,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720350544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,143<span></span>
</td>
<td class="nump">$ 57,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">17,989<span></span>
</td>
<td class="nump">58,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment (net of $2,797 and $2,272 depreciation, resepctively)</a></td>
<td class="nump">5,420<span></span>
</td>
<td class="nump">5,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents (net of $58,918 amortization and $556,120 impairment)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">23,409<span></span>
</td>
<td class="nump">64,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">71,439<span></span>
</td>
<td class="nump">69,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Current portion of notes payable - related party</a></td>
<td class="nump">183,889<span></span>
</td>
<td class="nump">167,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">27,953<span></span>
</td>
<td class="nump">28,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">9,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">284,452<span></span>
</td>
<td class="nump">274,104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">284,452<span></span>
</td>
<td class="nump">274,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Series A $0.10 par value per share; Authorized 850,000 Shares; Issued and outstanding -0- shares.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_PreferredStockValueSeriesB', window );">Preferred stock, Series B $0.10 par value per share; Authorized 500,000 Shares; Issued and outstanding 500,000 shares.</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 817,927,983 and 769,399,858 at March 31, 2017 and December 31, 2016, respectively. Reserved for issuance 204,918,033 at March 31, 2017</a></td>
<td class="nump">817,928<span></span>
</td>
<td class="nump">769,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital paid in excess of par value</a></td>
<td class="nump">11,642,783<span></span>
</td>
<td class="nump">11,548,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated comprehensive income</a></td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated (Deficit)</a></td>
<td class="num">(12,773,657)<span></span>
</td>
<td class="num">(12,577,954)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="num">(261,043)<span></span>
</td>
<td class="num">(209,700)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="nump">$ 23,409<span></span>
</td>
<td class="nump">$ 64,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PreferredStockValueSeriesB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PreferredStockValueSeriesB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720210176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Depreciation, equipment</a></td>
<td class="nump">$ 2,797<span></span>
</td>
<td class="nump">$ 2,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization, patent</a></td>
<td class="nump">$ 58,918<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">817,927,983<span></span>
</td>
<td class="nump">769,399,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">817,927,983<span></span>
</td>
<td class="nump">769,399,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance</a></td>
<td class="nump">204,918,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">850,000<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720925360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Statement Of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General &amp; Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Accounting</a></td>
<td class="nump">15,600<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Amortization &amp; depreciation</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">15,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_FinancialConsulting', window );">Consulting</a></td>
<td class="nump">25,937<span></span>
</td>
<td class="nump">14,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal</a></td>
<td class="nump">14,904<span></span>
</td>
<td class="nump">28,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_Office', window );">Office</a></td>
<td class="nump">7,401<span></span>
</td>
<td class="nump">3,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_OfficerRenumerationFee', window );">Officer &amp; director renumeration</a></td>
<td class="nump">42,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Stock Transfer Fee</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="nump">2,086<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total G &amp; A</a></td>
<td class="nump">108,990<span></span>
</td>
<td class="nump">69,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) from operations</a></td>
<td class="num">(108,990)<span></span>
</td>
<td class="num">(69,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Foreign exchange gain</a></td>
<td class="num">(639)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(9,144)<span></span>
</td>
<td class="num">(6,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Loss on debt conversions</a></td>
<td class="num">(76,929)<span></span>
</td>
<td class="num">(253,658)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other (Expense)</a></td>
<td class="num">(86,712)<span></span>
</td>
<td class="num">(235,612)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss)</a></td>
<td class="num">$ (195,702)<span></span>
</td>
<td class="num">$ (305,294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (Loss) per common share</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Oustanding</a></td>
<td class="nump">805,604,089<span></span>
</td>
<td class="nump">215,596,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (195,702)<span></span>
</td>
<td class="num">$ (305,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized Gain (Loss) from Foreign Exchange Translations</a></td>
<td class="nump">1,509<span></span>
</td>
<td class="num">(9,991)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (Loss)</a></td>
<td class="num">$ (194,193)<span></span>
</td>
<td class="num">$ (315,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (Loss) per common share</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Outstanding</a></td>
<td class="nump">805,604,089<span></span>
</td>
<td class="nump">215,596,040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_FinancialConsulting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_FinancialConsulting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_Office">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_Office</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_OfficerRenumerationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_OfficerRenumerationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=6928171&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720049248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Statement Of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Gain (Loss)</a></td>
<td class="num">$ (195,702)<span></span>
</td>
<td class="num">$ (305,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss</a></td>
<td class="nump">639<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">15,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_StockIssuedForPaymentInterest', window );">Stock issued for payment interest</a></td>
<td class="nump">3,022<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Loss on debt conversion</a></td>
<td class="nump">76,929<span></span>
</td>
<td class="nump">253,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_StockIssuedForPaymentOfExpenses', window );">Stock issued for payment of expenses</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">(Increase) decrease in prepaid expenses</a></td>
<td class="nump">161<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase (decrease) in Accounts Payable &amp; accrued expenses</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(52,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Increase (decrease) in interest payable</a></td>
<td class="num">(7,840)<span></span>
</td>
<td class="nump">3,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Flows (used) in operations</a></td>
<td class="num">(108,037)<span></span>
</td>
<td class="num">(81,598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchase of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Flows (used) in Investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceed from note payable</a></td>
<td class="nump">50,256<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_NotePayableUsedToPayExpenses', window );">Note payable used to pay expenses</a></td>
<td class="nump">13,962<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_NotePayableUsedToPayOrigionationFees', window );">Note payable used to pay origionation fees &amp; interest</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79,128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Flows provided by financing activities</a></td>
<td class="nump">66,218<span></span>
</td>
<td class="nump">164,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net Increase (Decrease) In Cash and cash equivalents</a></td>
<td class="num">(41,819)<span></span>
</td>
<td class="nump">82,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCash', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,509<span></span>
</td>
<td class="num">(9,991)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">57,453<span></span>
</td>
<td class="nump">50,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">17,143<span></span>
</td>
<td class="nump">123,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary Disclosure Of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock issued for services, licenses and other assets</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued for note conversions including interest</a></td>
<td class="nump">128,451<span></span>
</td>
<td class="nump">377,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_NotePayableUsedToPayExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_NotePayableUsedToPayExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_NotePayableUsedToPayOrigionationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_NotePayableUsedToPayOrigionationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_StockIssuedForPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_StockIssuedForPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_StockIssuedForPaymentOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_StockIssuedForPaymentOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of effect of exchange rate changes on cash balances held in foreign currencies. Excludes cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6711057472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. Descriptions of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">1. Descriptions of Business</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Mountain
West Business Solutions, Inc. (&#8220;MWBS&#8221;) was incorporated on August 31, 2006 in the State of Colorado. Sunshine Etopo,
Inc. (formerly Sunshine Biopharma, Inc.) was incorporated in the State of Colorado on August 17, 2009. Effective October 15, 2009,
MWBS was acquired by Sunshine Etopo, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its
name to Sunshine Biopharma, Inc. Sunshine Etopo, Inc. has been inactive and was recently dissolved. In July 2014, the Company
formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. The financial statements represent the consolidated
activity of Sunshine Biopharma, Inc. and Sunshine Biopharma Canada Inc. (hereinafter together referred to as the &#34;Company&#34;).
The Company was formed for the purposes of conducting research, development and commercialization of drugs for the treatment of
various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board
of Directors of the Company.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company&#8217;s wholly owned Canadian Subsidiary, Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;) was formed for
the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has recently
signed licensing agreements for four (4) generic prescription drugs for treatment of breast cancer, prostate cancer and BPH (Benign
Prostatic Hyperplasia). In addition, Sunshine Canada is currently evaluating several other generic products for in-licensing and
is working on securing a Drug Establishment License (&#8220;DEL&#8221;) and a Drug Identification Number (&#8220;DIN&#8221;) per
product from Health Canada. Once the DEL and the DIN&#8217;s are secured, Sunshine Canada will begin its generic pharmaceuticals
marketing and sales program in Canada and overseas.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
addition, the Company has been and continues to work on the development of its proprietary anticancer drug, Adva-27a. The next
series of steps in the development of Adva-27a include (i) GMP-manufacturing of a 2-kilogram quantity of the drug, (ii) completing
requisite IND-enabling studies, and (iii) conducting Phase I clinical trials. In the preclinical studies, Adva-27a was shown to
be effective at destroying multidrug resistant cancer cells including Pancreatic Cancer, Breast Cancer, Lung Cancer and Uterine
Sarcoma, cells.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During
the last three month period the Company has continued to raise money through stock sales and borrowings.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">The
Company&#8217;s activities are subject to significant risks and uncertainties, including failing to secure additional funding
to operationalize the Company&#8217;s generics business and proprietary drug development program.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618191552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">2. Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">See the Notes in the 2016 Form 10-K consolidated financial statements for a complete summary of the Company&#8217;s significant
accounting policies. This
summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements.
The consolidated financial statements and notes are representations of the Company's management, which is responsible for their
integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently
applied in the preparation of the financial statements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>PRINCIPLES
OF CONSOLIDATION</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany
accounts and transactions have been eliminated in consolidation.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>USE
OF ESTIMATES</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more
significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment,
and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased
the degree of uncertainty inherent in these estimates and assumptions.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>CASH
AND CASH EQUIVALENTS</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">For
the Balance Sheets and Statement of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered
to be cash equivalents. The Company had a cash balance of $17,143 and $57,453 as of March 31, 2017 and December 31, 2016, respectively.
At times such cash balances may be in excess of the FDIC limit of $250,000.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>EARNINGS
PER SHARE</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company has adopted the FASB ASC Topic 260 regarding earnings / loss per share, which provides for calculation of &#8220;basic&#8221;
and &#8220;diluted&#8221; earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing
net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings
/ loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted
earnings / loss per share.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Other
than the Notes Payable specified under Note 4 and Note 5 below, there were no potentially dilutive instruments outstanding during
the interim period ended March 31, 2017 or the year ended December 31, 2016.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>INCOME
TAXES</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires
the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between
financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There
was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes accrued
interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expense.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>FUNCTIONAL
CURRENCY</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the
Company's Canadian subsidiary is the Canadian dollar. The Company translates its Canadian subsidiary's financial statements into
U.S. dollars as follows:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Assets
    and liabilities are translated at the exchange rate in effect as of the financial statement date.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Income
    statement accounts are translated using the weighted average exchange rate for the period.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions
of a long-term investment nature as a separate component of shareholders&#8217; equity. There are currently no transactions of
a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>REVENUE
RECOGNITION</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Since
inception, the Company has been focused on the research, development and commercialization of drugs for the treatment of various
forms of cancer. Following its recent entry into the generic pharmaceuticals business, the Company has become a fully integrated
pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications.
The Company intends to recognize revenues from the sales of generic pharmaceuticals, if or when they occur, at the time the products
are sold and collectability is assured. In the event the Company provides consulting services in the future, revenues from
such services will be recognized when the services are rendered and invoiced.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>GOING
CONCERN</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and
the satisfaction of liabilities in the normal course of business. Since inception, the Company has had recurring operating losses
and negative operating cash flows. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going
concern.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
Company&#8217;s continuation as a going concern is dependent on its ability to obtain additional financing to fund operations,
implement its business model, and ultimately, attain profitable operations. The Company will need to secure additional funds through
various means, including equity and debt financing or any similar financing. There can be no assurance that the Company will be
able to obtain additional equity or debt financing, if and when needed, on terms acceptable to the Company, or at all. Any additional
equity or debt financing may involve substantial dilution to the Company&#8217;s stockholders, restrictive covenants or high interest
costs. The Company&#8217;s long-term liquidity also depends upon its ability to generate revenues and achieve profitability.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue
as a going concern.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6711059072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Unaudited Financial Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">3. Unaudited Financial Information</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
unaudited financial information included for the three month interim period ended March 31, 2017 was taken from the books and
records of the Company without audit. However, such information reflects all adjustments, consisting only of normal recurring
adjustments, which in the opinion of management are necessary to reflect properly the results of the interim periods presented.
The results of operations for the three month interim period ended March 31, 2017 are not necessarily indicative of the results
expected for the fiscal year ending December 31, 2017.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6613283680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">4. Notes Payable</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">A
Note Payable having a face value of $21,439 and a maturity date of December 31, 2017 was entered into on December 31, 2016. This
Note accrues interest at a rate of 12% per annum and is convertible after December 31, 2016 into $0.001 par value Common Stock
at a price 35% below market value. The Company estimates that the fair value of this convertible debt approximates the face value,
so no value has been assigned to the beneficial conversion feature.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">A
Note payable dated July 1, 2016, having a face value of $55,000 and a principal balance of $48,500 at December 31, 2016, accrued
interest at 10%. This note was convertible into $0.001 par value Common Stock at a price 40% below market value. During the three
month period ended March 31, 2017, a total of $48,500 in principal and $3,022 of interest was converted into $0.001 par value
Common Stock leaving a principal balance of $-0-. In connection with this conversion, 42,528,125 shares of $0.001 par value Common
Stock valued at $128,451 were issued generating a loss of $76,929 on conversion.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On
February 10, 2017, the Company received net proceeds of $48,000 in exchange for a note payable having a face value of
$50,000 and accruing interest at the rate of 8% per annum. The note, due on November 20, 2017, is convertible after 180 days
from issuance into $0.001 par value Common Stock at a price 39% below market value. The Company estimates that the fair value
of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. In
connection with this note, 204,918,033 shares of the Company&#8217;s Common Stock have been reserved for issuance.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">At
March 31, 2017 and December 31, 2016, accrued interest on Notes Payable was $15,124 and $9,011, respectively.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6711059072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Notes Payable Related Party<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_NotesPayableRelatedEntityAbstract', window );"><strong>Notes Payable Related Party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_DebtDisclosureRelatedEntityTextBlock', window );">5. Notes Payable Related Party</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In
December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian
($67,032 US) &#8217;&#8211;with interest at 12% due March 31, 2017. The note is convertible any time after the date of issuance
into $0.001 par value Common Stock at a price 35% below market value. The Company estimated that the fair value of the convertible
debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be
recognized at conversion. This note is collateralized by all of the assets of the Company. In the event of default, the interest
rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note,
together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US)
paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original
note. The new note now having a face value of $96,021 Canadian ($72,198 US) is due on June 30, 2017.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">A
note payable held by a private individual who became a principal shareholder of the Company having a face value of $100,000 at
December 31, 2016 and a maturity date of March 31, 2017, accrues interest at 12%. The Note is convertible any time from the date
of issuance into $0.001 par value Common Stock at a 35% discount from market price. The Company estimates that the fair value
of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. On March
31, 2017, the note&#8217;s principal balance of $100,000 plus accrued interest of $11,715 was renewed for a period of 90-day under
the same terms and conditions as the original note. The new note now having a face value of $111,715 matures on June 30, 2017.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DebtDisclosureRelatedEntityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DebtDisclosureRelatedEntityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_NotesPayableRelatedEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_NotesPayableRelatedEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617707520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Issuance of Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">6. Issuance of Common Stock</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During
the three months ended March 31, 2017, the Company issued a total of 48,428,125 shares of $0.001 par value Common Stock. Of these
42,428,125 shares valued at $128,451 were issued upon conversion of outstanding notes payable, reducing the debt by $48,500 and
interest payable by $3,022 and generating a loss on conversion of $76,929.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In
addition, the Company issued 6,000,000 shares of $0.001 par value Common Stock valued at $14,400 for $15,000
Canadian ($11,278 US). The $15,000 Canadian was paid directly to a firm which was engaged to conduct a valuation of the
Company&#8217;s patents. The difference of $3,122 was recorded as a consulting expense.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In
connection with its convertible notes payable, the Company has 204,918,033 shares of its common stock reserved for issuance
at March 31, 2017.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
Company declared no dividends through March 31, 2017.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6622255984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. Earnings (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_EarningsLossPerShareAbstract', window );"><strong>Earnings Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">7. Earnings (Loss) per Share</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Earnings
(loss) per share is computed using the weighted average number of Common Shares outstanding during the period. The Company has
adopted ASC 260 (formerly SFAS128), &#8220;Earnings per Share&#8221;.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarningsLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarningsLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617975520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Generic Drugs License<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_GenericDrugsLicenseAbstract', window );"><strong>Generic Drugs License</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_GenericDrugsLicenseDisclosureTextBlock', window );">8. Generic Drugs License</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In
2016, the Company entered into License Agreements for the following four Generic Drugs:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Anastrozole
    (brand name Arimidex&#174; by AstraZenica) for treatment of Breast Cancer</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; padding: 0.75pt"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Letrozole
    (brand name Femara&#174; by Novartis) for treatment of Breast Cancer</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding: 0.75pt; text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Bicalutamide
    (brand name Casodex&#174; by AstraZenica) for treatment of Prostate Cancer</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding: 0.75pt; text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Finasteride
    (brand name Propecia&#174; by Merck) for treatment of Benign Prostatic Hyperplasia</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
cost of these Licenses has been fully expensed.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_GenericDrugsLicenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_GenericDrugsLicenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_GenericDrugsLicenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_GenericDrugsLicenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6711069552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. Financial Statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_FinancialStatementsAbstract', window );"><strong>Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CondensedFinancialStatementsTextBlock', window );">9. Financial Statements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">For
a complete set of footnotes, reference is made to the Company&#8217;s Report on Form 10-K for the year ended December 31, 2016,
as filed with the Securities and Exchange Commission and the audited financial statements and notes included therein.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_FinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_FinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6622923232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">10. Income Taxes</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Deferred
income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses
and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">A
deferred tax asset at each date has been offset by a 100% valuation allowance.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6711069552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Royalties Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_RoyaltiesPayableDisclosureTextBlock', window );">11. Royalties Payable</a></td>
<td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">As
part of a subscription agreement entered into in 2016, the Company has an obligation to pay a royalty of 5% of net sales on one
of its generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_RoyaltiesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_RoyaltiesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6711022544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">12. Related Party Transactions</a></td>
<td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
addition to the related party transactions detailed in Note 5 above, during the three month period ended March 31, 2017, the Company
paid its Officers and Directors cash compensation totaling $42,965. $1,519 was paid to the Company&#8217;s COO and $41,446 was
paid to the Company&#8217;s CEO.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During
the fiscal year ended December 31, 2016, Advanomics Corporation paid on behalf of the Company $13,725 Canadian in patenting fees.
Advanomics was fully reimbursed by the Company in January 2017.&#160;</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6622143824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">13. Subsequent Events</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
April 2017, the Company received monies in exchange for a convertible note payable having a face value of $100,000 Canadian (approximately
$75,190 US).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
April 3, 2017, the Company sold 34,000,000 shares of its $0.001 par value Common Stock valued at $98,600 for $85,000
Canadian (approximately $63,912 US).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On
April 24, 2017, the Company issued 6,666,667 shares of its $0.001 par value Common Stock for the purchase of laboratory equipment
valued at $22,000.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On April
26, 2017, the Company received monies in exchange for a convertible note payable having a face value of $65,000. In
connection with this note, 100,000,000 shares of the Company&#8217;s Common Stock have been reserved for issuance.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618363248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">PRINCIPLES OF CONSOLIDATION</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have
been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements
in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions
made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation.
Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent
in these estimates and assumptions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the Balance Sheets and Statement
of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company
had a cash balance of $17,143 and $57,453 as of March 31, 2017 and December 31, 2016, respectively. At times such cash balances
may be in excess of the FDIC limit of $250,000.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted the FASB ASC
Topic 260 regarding earnings / loss per share, which provides for calculation of &#8220;basic&#8221; and &#8220;diluted&#8221;
earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available
to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect
the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per
share.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">Other than the Notes Payable specified under Note 4 and Note
5 below, there were no potentially dilutive instruments outstanding during the interim period ended March 31, 2017 or the year
ended December 31, 2016.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="margin: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">The
Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires
the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between
financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There
was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">FOREIGN CURRENCY</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The U.S. dollar is the functional currency of the Company
which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar.
The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 48px; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 48px; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Income statement accounts are translated using the weighted average exchange rate for the period.</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company includes translation adjustments
from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as
a separate component of shareholders&#8217; equity. There are currently no transactions of a long-term investment nature, nor any
gains or losses from non-U.S. currency transactions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">Since inception, the Company has been focused on the research,
development and commercialization of drugs for the treatment of various forms of cancer. Following its recent entry into the generic
pharmaceuticals business, the Company has become a fully integrated pharmaceutical company offering generic and proprietary drugs
for the treatment of cancer and other acute and chronic indications. The Company intends to recognize revenues from the sales of
generic pharmaceuticals, if or when they occur, at the time the products are sold and collectability is assured. In the
event the Company provides consulting services in the future, revenues from such services will be recognized when the services
are rendered and invoiced.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The accompanying financial statements have been prepared on
a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of
business. Since inception, the Company has had recurring operating losses and negative operating cash flows. These factors raise
substantial doubt about the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The Company&#8217;s continuation as a going concern is dependent
on its ability to obtain additional financing to fund operations, implement its business model, and ultimately, attain profitable
operations. The Company will need to secure additional funds through various means, including equity and debt financing or any
similar financing. There can be no assurance that the Company will be able to obtain additional equity or debt financing, if and
when needed, on terms acceptable to the Company, or at all. Any additional equity or debt financing may involve substantial dilution
to the Company&#8217;s stockholders, restrictive covenants or high interest costs. The Company&#8217;s long-term liquidity also
depends upon its ability to generate revenues and achieve profitability.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The accompanying financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that
might be necessary should the Company be unable to continue as a going concern.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=64819266&amp;loc=SL51888449-203568<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=64819266&amp;loc=SL51888443-203568<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6874517456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract', window );"><strong>Summary Of Significant Accounting Policies Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,143<span></span>
</td>
<td class="nump">$ 57,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6874978608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>4. Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SBFM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest accrued</a></td>
<td class="nump">$ 1,171<span></span>
</td>
<td class="nump">$ 9,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6874630560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Issuance of Common Stock (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issuance of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued</a></td>
<td class="nump">48,428,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>37
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NQ[Z_;N'QM?!%4#O^Y"?0%02P,$%     @ )7VL2IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MN1BZ[K!0O!M?%,'TK"G^ %!+ P04    "  E?:Q*W/*O]X #  !Z#P  &
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(6776^;,!2&_PKBOL4V-L95$FG)
M-&W2)E6;MEW3Q$E0 6= DN[?SQ :D7,.62_*1]YC/^;C,9Z=7?W:[*UM@[>R
MJ)IYN&_;PU,4->N]+;/FT1ULY7_9NKK,6G]8[Z+F4-MLTQ>512082Z(RRZMP
M,>O//=>+F3NV15[9YSIHCF69U7^7MG#G><C#]Q/?\]V^[4Y$B]DAV]D?MOUY
M>*[]471M99.7MFIR5P6UW<[##_QI)517T"=^Y?;<C/:#;B@OSKUV!U\V\Y!U
M1+:PZ[9K(O.;DUW9HNA:\AQ_AD;#:Y]=X7C_O?5/_>#]8%ZRQJY<\3O?M/MY
MF(;!QFZS8]%^=^?/=AB0"H-A]%_MR18^WI'X/M:N:/K_P?K8M*X<6O$H9?9V
MV>95OST/[;^7T05B*!#7 B[O%L1#00P*H@M9/]2/69LM9K4[!_7E;AVR[J'@
M3[&_F.ON9'_M^M_\:!M_]K00>A:=NG:&R/(2$>/(;6)%)-)K)/+]7R$$"2'Z
M^GA<;^CZF*R/^WHYJH\9&,0EHOM(U4>XYC(& \$II:6*:19)LDC,P@'+):)&
MO:0R 20XPQG3-(@B010& ?=MJ7 GVJ0&H."4\KR,9DE(E@2S@$N_3' O4H"[
MN")"1DJ:1),D&I-(0*)1)Q#C7N*&(2494LR@ $.*>A"Q9/#.X%0B)9NX'H9D
M,>C5BQ.ZGC-:( R/!AF$(=#NY8/#(6*),?&$"OB$T#CF22$/QP]^&J?HR:=R
MB6:C]^B6B+8;%YC(0"*!;[@V"OJ)BJ5<3/'0MN18EQ+J<LC<C-P+$^+@E&&<
M3]#0ON18F!(*DV,;BE1*A>8A(J<EGWHC."U.CLTIH3DYEB)-1.3N$='ZY-B?
M<.I:4AD):>YF;DEH?7*-?"'51 NT_#BV'YS\EAR+#2KX;N26@Q8?-Y@#><O@
M^8;Y/\CRO]CM)Q#M48$]*J&W!!9DZF=L 7(K(J<3(R>):),*;%()O24(0_)$
M"IU"=9%)):>_),3$MR*VJ8+V$EB3W#!$A%.QF7@=!*U2@56JH+P$EN0#%UK'
MB=*0B(PJ[6>"*2Y:J@)+%:II*; L'T3BU82N$Q5D1D\^3K16!=8JG-^60V;\
M 4Y]]Q QZL,G&BV"NE7IMZS>Y543O+C6KZ?Z5<_6N=;Z)MFC;W+O%\+7@\)N
MVVY7^_WZLAJ\'+3N,*QTH^MR>_$/4$L#!!0    ( "5]K$H4TLW:YP(  (0,
M   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC9?=CMHP$(5?)<H#;&+G
M?P5(A:IJI59:;=7VV@L&HDWBU#:P??LZCHD2>R!P06+GS,QG&!\YBPOC[^)(
MJ?0^ZJH12_\H9?L<!&)[I#413ZREC7JR9[PF4@WY(1 MIV2G@^HJP&&8!C4I
M&W^UT',O?+5@)UF5#7WAGCC5->'_UK1BEZ6/_.O$:WDXRFXB6"U:<J _J?S5
MOG U"H8LN[*FC2A9XW&Z7_J?T/,&ZP"M^%W2BQC=>]U2WAA[[P;?=DL_[(AH
M1;>R2T'4Y4PWM*JZ3(KCKTGJ#S6[P/']-?L7O7BUF#<BZ(95?\J=/"[]W/=V
M=$].E7QEEZ_4+"CQ/;/Z[_1,*R7O2%2-+:N$_O:V)R%9;;(HE)I\]->RT==+
M_R3&)@P.P"8 #P$HOAL0F8#("@AZ,KW4ST22U8*SB\?[?ZLE75.@YTC]F-MN
M4O]V^IE:K5"SYU42+X)SE\=(UKT$CR1XJM@ BGR0!*K^ (%!"*SCXS%$8D'T
MDDQ+FKY$5F06!R#"&89)(I D<DE2BR1RBB1Y@7(+Q56%,$<,<L0Z/!IS9'!\
M L8G[CHLPG4OR<>$3V&(K'7,J28L*<B2NBR%Q=)+DE&5*+Q^+*"'I!.J#*3*
M'*K4*K7.G%(YR@K5=WED0;G*+"VBHLB3&_L@!YERE\GZ/];YPTRN<H:I )D*
ME\G:_NO"J83#6&V),(K@2BB$O2AT:]W*<,/-T,/[!L%6A%PO2AU#[#7%9%/8
M&V=&-&6!S0BY;I3:OF@TDX9(@&TSKYL2P;:$8I?(]D>C24#K,S#W)%,.V-Z0
MZV]I9G,D\QSW)%,.V-J0ZVWIC=V%8!M"V>,="YL& ES#Z=C\D8Z]+YJRP&:!
M +=P.M:UBP0R^GG=]&0!>PH&/,7N6*.9)9K738E@C\)HOG>-9IYH5M<3!:/C
M8'<^_T'XH6R$]\:D.EGJ\]^>,4E5SO!)93NJ5X)A4-&][&XS=<_[<W$_D*PU
M9_Y@>/%8_0=02P,$%     @ )7VL2ATP6@;A P  <1$  !@   !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6R%F%VOHS80AO\*XCZ+/6!C'R613K):M5(K'6W5
M]IJ3.!]:P"F0D^V_K_G8+/&,TYL YAW/.Q@_L5G>;/.M/1G31=^KLFY7\:GK
M+B])TNY.IBK:3_9B:G?G8)NJZ-QE<TS:2V.*_1!4E0DP)I.J.-?Q>CFTO37K
MI;UVY;DV;TW47JNJ:/[=F-+>5C&/?S1\/1]/7=^0K)>7XFC^,-V?E[?&727W
M7O;GRM3MV=918PZK^)6_;$'W 8/BK[.YM;/SJ"_EW=IO_<6O^U7,>D>F-+NN
M[Z)PAP^S-679]^1\_#-U&M]S]H'S\Q^]?QF*=\6\%ZW9VO+O\[X[K6(51WMS
M**YE]]7>?C%302*.INI_,Q^F=/+>B<NQLV4[_$:[:]O9:NK%6:F*[^/Q7 _'
MVWA'YE,8'0!3 -P#7.YG >D4D/X,R(;B1V=#J9^+KE@O&WN+FG&T+D7_4O"7
MU#W,7=\X/+OAGJNV=:T?:ZF7R4??SR39C!*82?A=D;C.[QF RK !% Z/";98
MD3,Z0TK6D [QZ3P^X# CX[,A/IO'>Q8WHR0?)/4@85X1SQ0/'@3I0> :4CI>
MDO$2UY!Y-8P2,7/(A61^'5@E%0N4DI-6<FQ%>%9RE$1PY1G!&BX@RV@GBG2B
ML!/I.5$H"PB=YIX7K.(95P$OFO2BL1<ORT83633SAG&+5:"8UK07SNA9S[ ;
MY4][AA+E&>.>&T*5@@RY"3"(8S<(0ASER4!+X=O!LL"[RTE:O7) 7A3SO0 >
M*(FM8!4P)0-N:++Q%+OAOIL4NV%*:W]B$SJII8* (1J5'+-2^:R<-/-$"]H1
M(7QFB28GQ^A4 71RFIT<PU/Y\.28BPN9:K\BK J]?C0[.8:G\N'),1D7FF<^
M)RB9U"( +4X3E&.$*A^A'-,1C32%61;Z6^$T03E&J/(1RC$=%[G4@ :*T(%(
MI5"T): Y"IBCRN<H8$(NE,PY6@41.DB%Y('I #1, <-4^3"=-/G##-4B9\@3
M(4R9 !UXBX"&*F"H^C#83)IG2ZRGDD<?-$X!XU3[. 6,2<7<.BEC_F/<$E+@
M0NA>'/!%4Q4P5;5/5< +S,"8$<*G8T9C%3!6=0"K0&,5,%:UCU6@%J4,/6@"
MOEKKT#:$1BM@M&H?K9/&>\@9GU4^.2*$J5N?SF#]Z(G&*V"\XHFA_G]B/),\
M^J#1"ABMVL<\8&0&)P:Q1@U,C&2V4:U,<QSV]&VTL]>ZZ_>$L];[=X-7Z#>Z
M7ON&OVS'W?_/;L:/$;\7S?%<M]&[[=PV>MCL'JSMC'/*/CF/)U/L[Q>E.73]
M:>[.F_$CP'C1V<OT@2.Y?V59_P=02P,$%     @ )7VL2K7^YK8+!   QA(
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MG\T\9K/A<%A^$%N_<?D34$L#!!0    ( "5]K$J V71.L $  -(#   8
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M>0%FF'/FS#"D YIGVP X\J)5:S/:.-?M&;-% UK8"^R@]3<5&BV<-TW-;&=
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M2/Y*PE8]U6";.$V.E&;HXB2OO,O WO/X)K_#IVG_(FPC.T>NQN/+QO[7QGA
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M[O%LQS$;#6^ZZ0>Q^1OG?P!02P,$%     @ )7VL2M#)U42U 0  T@,  !D
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M]NC:)!1+O'<.N,S6\=YU 8XP@H=X;//86H$ICRB9;!U89V$,;LXZL%BULFK
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M+LF#CI*%*Z^A'=$IWMY&>/!FD!;WF=LS!_V?&Z]'/"C0G@6?RZ=@]B!E3%K
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M0B*Y&S6ASR,<.%3N"@MS!>2#,!/>)CZE&UX@1X(]-NL[H8C0V=A_I-%* &/
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M$CS9'R&G+7_M"DY/SO0;4$L#!!0    ( "5]K$J-)!#?G@(  -8.   /
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M+RYR96QS4$L! A0#%     @ )7VL2F;S"V""    L0   !
M ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  E?:Q*6>(9Q^\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ )7VL2A32S=KG @
MA P  !@              ( !8 \  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( "5]K$H=,%H&X0,  '$1   8              "  7T2
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  E?:Q*M?[F
MM@L$  #&$@  &               @ &4%@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ )7VL2DS--2.Q 0  T@,  !@
M ( !U1H  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "5]
MK$I*383YLP$  -(#   8              "  ;P<  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    "  E?:Q*@-ET3K !  #2 P  &
M        @ &E'@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( "5]K$HLV)CAM0$  -(#   9              "
M 34H  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ )7VL
M2F<0'L"S 0  T@,  !D              ( !(2H  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    "  E?:Q*!_80T+0!  #2 P  &0
M        @ $++   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( "5]K$I^TO6)M $  -(#   9              "  ?8M  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ )7VL2M#)U42U 0  T@,
M !D              ( !X2\  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    "  E?:Q*3>R=L+,!  #2 P  &0              @ '-,0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "5]K$K04I(V
M%0(  )P&   9              "  ;<S  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ )7VL2O8?R*VU 0  TP,  !D
M ( ! S8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  E
M?:Q*;TY0!K,!  #2 P  &0              @ 'O-P  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "5]K$H/=0#VYP$  +@$   9
M          "  =DY  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#
M%     @ )7VL2AVQ^=+F'P  <7D  !0              ( !]SL  'AL+W-H
M87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ )7VL2JH^41 Z @  ?PH   T
M             ( !#UP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  E?:Q*
MC200WYX"  #6#@  #P              @ %T7@  >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ )7VL2CS'N'9" 0  APX  !H              ( !/V$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ )7VL2DX5
M-@UO 0  C \  !,              ( !N6(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&     !\ 'P!+"   660

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>11</ContextCount>
  <ElementCount>110</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheet (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BalanceSheet</Role>
      <ShortName>Balance Sheet (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheet (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BalanceSheetParenthetical</Role>
      <ShortName>Balance Sheet (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Unaudited Statement Of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/UnauditedStatementOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Unaudited Statement Of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Unaudited Statement Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows</Role>
      <ShortName>Unaudited Statement Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - 1. Descriptions of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/DescriptionsOfBusiness</Role>
      <ShortName>1. Descriptions of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - 2. Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>2. Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 3. Unaudited Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/UnauditedFinancialInformation</Role>
      <ShortName>3. Unaudited Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 4. Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://sunshinebiopharma.com/role/NotesPayable</Role>
      <ShortName>4. Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 5. Notes Payable Related Party</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://sunshinebiopharma.com/role/NotesPayableRelatedParty</Role>
      <ShortName>5. Notes Payable Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 6. Issuance of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IssuanceOfCommonStock</Role>
      <ShortName>6. Issuance of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 7. Earnings (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/EarningsLossPerShare</Role>
      <ShortName>7. Earnings (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 8. Generic Drugs License</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/GenericDrugsLicense</Role>
      <ShortName>8. Generic Drugs License</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 9. Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/FinancialStatements</Role>
      <ShortName>9. Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 10. Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IncomeTaxes</Role>
      <ShortName>10. Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 11. Royalties Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/RoyaltiesPayable</Role>
      <ShortName>11. Royalties Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 12. Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>12. Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 13. Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SubsequentEvents</Role>
      <ShortName>13. Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>2. Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>2. Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - 4. Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>4. Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/NotesPayable</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sbfm-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - 6. Issuance of Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative</Role>
      <ShortName>6. Issuance of Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IssuanceOfCommonStock</ParentRole>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sbfm-20170331.xml</File>
    <File>sbfm-20170331.xsd</File>
    <File>sbfm-20170331_cal.xml</File>
    <File>sbfm-20170331_def.xml</File>
    <File>sbfm-20170331_lab.xml</File>
    <File>sbfm-20170331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>43
<FILENAME>0001654954-17-004568-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-17-004568-xbrl.zip
M4$L#!!0    ( "5]K$I$PVK<5BT  'Q  0 1    <V)F;2TR,#$W,#,S,2YX
M;6SM?6MSVSBRZ/=;=?\#;DYF3U(EVZ+>2F;FE.)'QKL9VVL[^SA?3L$D)/&$
M(K4DY<?^^MO= $A0(B52HAU[XJW:C"R1Z$:CN]%H]./G_[J?>>Q6A)$;^+^\
ML?:;;YCP[<!Q_<DO;[Y>[8VN#D]/W[#_^O7__A\&__OY_^WML1-7>,X'=A38
M>Z?^./C(SOA,?&"?A2]"'@?A1_8W[BW@F[_^X]2/X3L[=F\%?"O!?&"=?6O
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MF01G"]AT;% .<WF5@;I=HX""(KQ(W*$4,Q["WN40Q]T%H><8BE ]/S6T'>&
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MRW0@+:5VF@\_A.4=RUH!PO/F&*GD3S O3<.]<YUX^H%9S>9/%>.TDN'#K>:
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MM)JFCQCZ#B7_)4ZN-#!+128)E5,$\ I(TF#N&#7DW530*L*D;%",#6W#8W"
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M-* \<85YZ.I*H]S1;]DM<!A@NB.,GM.F\0]RH:';.IA-$@71?1P$,3G;\!9
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M?F"*JJ5>GR"AAZHAZE[5C!)Z<)A*-+Q+/,IH-,=F_ ?; $K5UR\Q<U&,A=;
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MK81/*\5<9_!XK<EW)%B:ZU_Z/U^!*_\#4$L#!!0    ( "5]K$IE(&2.]R
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M[8ED&LX98P23[X>J4G"E)OGO-']Z(0ZUB=W"*O(Q!GK6F&1B1DTF'248?#)
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M0NR3?P-02P$"% ,4    "  E?:Q*1,-JW%8M  !\0 $ $0
M@ $     <V)F;2TR,#$W,#,S,2YX;6Q02P$"% ,4    "  E?:Q*2QSUX#@(
M   +1   $0              @ &%+0  <V)F;2TR,#$W,#,S,2YX<V102P$"
M% ,4    "  E?:Q*1F*L!&<+  !M@   %0              @ 'L-0  <V)F
M;2TR,#$W,#,S,5]C86PN>&UL4$L! A0#%     @ )7VL2H9EG1\&"   $$@
M !4              ( !AD$  '-B9FTM,C Q-S S,S%?9&5F+GAM;%!+ 0(4
M Q0    ( "5]K$IE(&2.]R   +.V 0 5              "  ;])  !S8F9M
M+3(P,3<P,S,Q7VQA8BYX;6Q02P$"% ,4    "  E?:Q*95!#['86   Y10$
M%0              @ 'I:@  <V)F;2TR,#$W,#,S,5]P<F4N>&UL4$L%!@
0   &  8 B@$  )*!      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
